{"title": "PDF", "author": "PDF", "url": "https://www.swissmedic.ch/dam/swissmedic/de/dokumente/zulassung/swisspar/68225-comirnaty-01-swisspar-20210430.pdf.download.pdf/20210430_SwissPAR%20Comirnaty.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n \nSwissPAR  \n   1 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \nDate:  30 April 2021  \nSwissmedic, Swiss Agency for Therapeutic Products  \n \n \n \nSwiss Public Assessment Report  \n  \n \nComirnaty c oncentrate for dispersion for injection  \nCOVID -19 mRNA Vaccine (nucleoside modified)  \n \n \nInternational non- proprietary name:  tozinameranum ( single -stranded, 5\u2019 -\ncapped messenger RNA (mRNA) produced using a cell -free in vitro \ntranscription from the corresponding DNA templates, encoding the viral spike \n(S) protein of SARS-CoV -2). \nPharmaceutical form:  Concentrate for dispersion for injection  (sterile \nconcentrate).  \nDosage strength:  1 dose (0.3 mL) contains 3 0 micrograms of COVID -19 \nmRNA V accine (embedded in lipid nanoparticles).  \nRoute(s) of administration:  Comirnaty should be  administered intramuscularly  \nMarket ing Authorisation Holder:  Pfizer AG, Z urich  \nMarketing Authorisation No. : 68225  \nDecision and Decision date:  approved on  19.12.2020, (temporary \nauthorisation in accordance with Art. 9a TPA)   \n \n \nNote:  \nAssessment Report as adopted by Swissmedic with all information of a commercially confidential \nnature deleted.    \n \nSwissPAR  \n   2 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \nAbout Swissmedic  \nSwissmedic is the Swiss authority responsible for the authorisation and supervision of therapeutic \nproducts. Swissmedic's activities are based on the Federal Act of 15 December 2000 (Status as of  \n1 January 2020)  on Medicinal Products and Medical Devices ( TPA, SR 812.21). The agency ensures \nthat only high -quality , safe and effective drugs  are available in Switzerland, thus mak ing an important \ncontribution to the protection of human health.  \n \nAbout the Swiss Public Assessment Report ( SwissPAR ) \n\uf0a7 The SwissPAR is referred to in Article 67 para . 1 of the Therapeutic Products Act and the \nimplementing provisions of Art. 68 para. 1 let. e of the Ordinance of 21 September 2018 on \nTherapeutic  Products (TPO, SR 812.212.21).  \n\uf0a7 The SwissPAR provides information about the evaluation of a prescription medicine and the \nconsiderations that led Swissmedic to approve or not approve a prescription medi cine submission. \nThe report focuses on the transparent presentation of the benefit -risk profile of the medicinal \nproduct.  \n\uf0a7 A SwissPAR is produced for all human medicinal products with a new active substance and \ntransplant products for which a decision to approve or reject  an authorisation application has been \nissued.  \n\uf0a7 A supplementary report  will be published for approved or rejected applications for an additional \nindication for a human medicinal product for which a SwissPAR has been published following the \ninitial authorisation.  \n\uf0a7 The SwissPAR is written by Swissmedic  and is published on the Swissmedic website.  Information \nfrom the application documentation is not published if publication would disclose commercial or manufacturing secrets.  \n\uf0a7 The SwissPAR is a \u201c final\u201d document,  which  provides  information relating  to a submission at a \nparticular point in time  and will not be updated after publication.  \n\uf0a7 In addition to the actual SwissPAR, a concise version of SwissPAR that is more comprehensible \nto lay persons (Publi c Summary SwissPAR) is also published.   \n   \n \nSwissPAR  \n   3 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \nTable of contents  \n1 Terms, Definitions, Abbreviations  .................................................................................... 4 \n2 Background Information on the Procedure  ..................................................................... 5 \n2.1 Applicant\u2019s Request(s)  ......................................................................................................... 5 \n2.2 Indication and Dosage  ......................................................................................................... 5 \n2.2.1  Requested Indication  ........................................................................................................... 5 \n2.2.2  Approved Indication  ............................................................................................................. 5 \n2.2.3  Requested Dosage  .............................................................................................................. 5 \n2.2.4  Approved Dosage  ................................................................................................................ 6 \n2.3 Regulatory History (Milestones)  ........................................................................................... 6 \n3 Medical Context  ................................................................................................................. 7 \n4 Quality Aspects  ................................................................................................................. 7 \n4.1 Drug Substance  ................................................................................................................... 7 \n4.2 Drug Product  ....................................................................................................................... 8 \n4.3 Quality Conclu sions  ............................................................................................................. 9 \n5 Nonclinical Aspects......................................................................................................... 10 \n6 Clinical and Clinical Pharmacology Aspects  .................................................................  13 \n6.1 Clinical Pharmacology  ....................................................................................................... 13 \n6.2 Dose Finding and Dose Recommendation  ......................................................................... 17 \n6.3 Efficacy  .............................................................................................................................. 18 \n6.4 Safety  ................................................................................................................................ 23 \n6.5 Final Clinical and  Clinical Pharmacology Benefit Risk Assessment  ................................... 26 \n6.6 Approved Indication and Dosage  ....................................................................................... 27 \n7 Risk Management Plan Summary  ................................................................................... 28 \n8 Appendix  .......................................................................................................................... 29 \n8.1 Approved Informati on for Healthcare Professionals  ........................................................... 29 \n \n   \n \nSwissPAR  \n   4 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n1 Terms, Definitions, Abbreviations  \nADA Anti-drug antibody  \nADME  Absorption, Distribution, Metabolism, Elimination  \nALT Alanine aminotransferase \nAPI Active pharmaceutical ingredient  \nATC Anatomical Therapeutic Chemical Classification System  \nAUC  Area under the plasma concentration- time curve  \nAUC0 -24h Area under the plasma concentration- time curve for the 24 -hour dosing interval  \nBAG  Bundesamt f\u00fcr Gesundheit (Swiss Federal Office of Public Health)  \nCMI Cell-mediated immunity  \nCOVID -19      Coronavirus disease caused by the SARS- CoV-2 virus  \nCmax  Maximum observed plasma/serum concentration of drug \nCYP Cytochrome P450  \nERA Environmental Risk Assessment  \nFIH First in Human  \nGMC  Geometric mean concentration \nGMT  Geometric mean titre  \nHCS   Human convalescent sera \nGLP Good Laboratory Practice  \nICH  International Council for Harmonisation  \nICS Intracellular cytokine staining \nIg Immunoglobulin \nIMM Immunogenicity set  \nIMP Investigational medicinal product  \nINN International Nonproprietary Name  \nLNP Lipid nanoparticle \nLoQ List of Questions  \nMAH  Market ing Authorisation Holder  \nMax Maximum  \nMin Minimum  \nN/A Not applicable \nNO(A)EL  No Observed (Adverse) Effect Level  \nPD Pharmacodynamic s \nPIP Paediatric Investigation Plan (EMA)  \nPK Pharmacokinetic s \nPopPK Population PK  \nPSP Paediatric Study Plan (US -FDA)  \nRBD  Receptor -binding domain \nRMP  Risk Management Plan \nSARS- CoV-2  Severe Acute Respiratory Syndrome Coronavirus 2  \nSwissPAR  Swiss Public Assessment Report  \nTPA Federal Act of 15 December 2000  (Status as of 1 January 2020)  on Medicinal Products \nand Medical Devices  (SR 812.21)  \nTPO Ordinance of 21 September 2018  (Status as of 1 April 2020)  on Therapeutic Products \n(SR 812.212.21)  \nWHO  World Health Organisation \n\u00b5g  Microgram    \n \nSwissPAR  \n   5 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n2 Background Information on the Procedure  \n2.1 Applicant\u2019s Request(s)  \nNew A ctive Substance status  \nThe applicant requested the status of a new active entity for the active substance tozinameran \n(single -stranded, 5\u2019 -capped messenger RNA (mRNA) produced using a cell -free in vitro transcription \nfrom the corresponding DNA templates, encoding the viral spike (S) protein of SARS -CoV-2) of the \nmedic inal product mentioned above.  \n \nRolling  authorisation procedure ( FTP) \nThe applicant requested a rolling  authori sation procedure.  According to the Guidance document  \n\u201cAuthorisation procedures for COVID -19 medicinal products during a pandemic , HMV4\u201d,  for the \nexceptional case of a pandemic, and at the request of the applicant during a Presubmission Advice \nmeeting, an authorisation application may be submitted as a \"Rolling Submission\". The \"Rolling \nSubmission\" procedure represents a special form of a first authorisation procedure or a variation \nprocedure.    \n Marketing authorisation for human medical products  \nThe applicant requested a marketing authorisation in accordance with Art. 9 a, para. 1 TPA.  However, \nbased on the submitted clinical data material and the results of the evaluation, Swissmedic granted a \ntemporary authorisation in accordance with Art. 9a TPA  and with regard to the guidance document \n\u201cAuthorisation procedures for COVID -19 medicinal  products during a pandemic, HMV4\u201d.  \n \nOPEN project EMA  \nIn the context of the EMA's OPEN project, Swissmedic has been participating in the meetings of the \nCHMP. Further information at: EMA COVID -19 assessments \u2018OPEN\u2019 to non- EU regulators | European \nMedicines  Agency (europa.eu).  \n \n2.2 Indication and Dosage  \n2.2.1  Requested Indication  \nActive immunisation to prevent COVID -19 disease caused by SARS -CoV-2 virus, in individuals 16 \nyears of age and older.  \nThe use of Comirnaty vaccine should be in accordance with official guidance . \n2.2.2  Approved Indication  \nComirnaty is indicated for active immunisation to prevent COVID -19 caused by SARS -CoV-2 virus, in \nindividuals 16 years of ag e and older. The use of this v accine should be in accordance with official \nrecommendations.  \n2.2.3  Requested Dosage  \nTo ensure traceability of biotechnological medicinal products, it is recommended that the trade name \nand batch number should be documented for each treatment.  \n \nIndividuals  16 years of age and older  \nComirnaty is administered intramuscularly after dilution as a series of two doses (0.3 ml each) at \ngreater than or equal to 21 days apart.  \nThere are no data available on the interchangeability of Comirnaty with other COVID -19 vaccines to \ncomplete the vaccination series. Individuals who have received one dose of Comirnaty should receive a second dose of Comirnaty to complete the vaccination series.  \nIndividuals may not be protected until at least 7  days after their second dose of the vaccine.   \n \nSwissPAR  \n   6 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n2.2.4  Approved Dosage  \n(see appendix)  \n \n2.3 Regulatory History ( Milestones)  \nApplication  16 October 2020  \nFormal control completed  16 October 2020  \nList of Questions (LoQ)  Rolling Lists of Questions  \nAnswers to LoQ  Rolling Answers to List of Questions  \nPredecision  18 December 2020  \nAnswers to Predecision  19 December 2020  \nLabelling corrections  18 December 2020  \nAnswers to Labelling corrections:  19 December 2020  \nFinal Decision  19 December 2020  \nDecision  approval  (temporary authorisation in accordance with Art. \n9a TPA) \n \n \n   \n \nSwissPAR  \n   7 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n3 Medical Context  \nCOVID -19 is an infectious disease caused by the coronavirus SARS -CoV-2. COVID -19 is an \ninfectious disease caused by the coronavirus SARS -CoV-2. WHO Coronavirus  Disease (COVID- 19) \nDashboard | WHO Coronavirus Disease (COVID -19) Dashboard ) reports on the number of cases and \ndeaths globally and per country. As of 27 February 2021, there have been, globally, 113, 076,707 \nconfirmed cases of COVID -19, including 2 ,512,272 deaths.  \n \nIn Switzerland, epidemiological data on COVID -19 are collected by the Swiss Federal Office of Public \nHealth (BAG, Bundesamt f\u00fcr Gesundheitswesen), Situation in Switzerland (admin.ch)  and  \n(BAG_COVID -19_Woechentliche_Lage.pdf ). Cumulatively and up to February 21, 2021, there have \nbeen 550, 066 confirmed cases of COVID -19 (6, 391.6 per 100 ,000 inhabitants),  \n23,617 hospitali sations (274.4 per 100 ,000 inhabitants) and 9, 204 deaths (106.9 per 100 ,000 \ninhabitants).  \n \nWhile hospitali sations occur in every age group, more than 80% of hospitali sations in Switzerland are \nin people aged 50 and over, with incidence increasing with age.  \n Underlying health conditions such as hypertension, cardiovascular di sease, diabetes, chronic \nrespiratory disease, chronic kidney disease, immuno compromised status, cancer and obesity are \nconsidered risk factors for the development of severe COVID -19.  \n \nSymptoms may appear 2 -14 days after exposure to the virus. Symptoms may  include: fever or chills, \ncough, shortness of breath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore \nthroat, congestion or runny nose, nausea or vomiting, diarrhoea. Severe COVID -19 can cause \ndyspnoea, pneumonia and ARDS (Acute Respiratory Distress Syndrome), thromboembolism and \nother conditions that may require ICU care. In addition to respiratory sequelae, severe COVID -19 has \nbeen linked to cardiovascular and renal sequelae and neurological complications . Among those who \nhave died, the time from symptom onset to death has ranged from two to eight weeks.  \n \n4 Quality Aspects  \n4.1 Drug Substance  \nDrug Substance  \nBNT162b2 (tozinameran), the active substance of Comirnaty, is a single- stranded, 5\u2019 -capped mRNA \nencoding S1S2 , the full-length surface antigen from the SARS- CoV-2 virus. The S1S2 protein \nsequence includes an intrinsic signal peptide at the N-terminal end and two proline point mutations \nresulting in the protein in the optimi sed prefusion conformation. The RNA sequence contains common \nstructural elements, such as 5\u2019cap, 5\u2019 and 3\u2019 UTRs, poly(A) tail. Uridine in the full sequence is replaced by N -methyl pseudouridine.   \nThe mRNA drug substance is formulated with lipid nanoparticles for the protection of mRNA after administ ration and to facilitate transfection into the host cells. Upon uptake, mRNA is released and \ntranslated in the cell to generate the encoded S1S2 protein antigen.  \n The d rug substance is manufactured in  a cell-free system by an in vitro  transcription reacti on using \nenzymatic reagents and utili sing nucleotide triphosphates, a 5\u2019-cap structure and lineari sed plasmid \ntemplate as starting materials. The in vitro  transcription reaction is followed by several purification and \nfiltration steps. The purified drug substance is filled into the primary containers and frozen.  \nLineari sed plasmid is not a structural component of the drug substance but serves as a template for \nthe respective enzyme, thus defining the correct nucleotide sequence of the mRNA drug substance. \nPlasmid is produced by fermentation in established and characteri sed bacterial cell banks. For \nplasmid manufacture and control, sufficient information was provided.  \n  \n \nSwissPAR  \n   8 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \nManufacturing process changes during the process development , including new manufacturing sites, \nprocess changes and scale- up, were adequately described,  and supporting data from comparability \nstudies between commercial and clinical batches were provided. Drug substance and its impurities \nwere sufficiently character ised using state -of-the-art analytical methods.  \nThe process performance qualification runs were performed , and the presented control strategy, \nvalidation data and extended characteri sation results demonstrated that the manufacturing process is \ncapable of p roducing drug substance batches that consistently meet the requirements.  \n \nThe specification tests and acceptance criteria were provided and include e.g. identity test, purity and \nimpurit y testing. Analytical methods were described,  and non- compendial methods have been \nvalidated in accordance with ICH guidelines.  \n A shelf -life proposed for the drug substance stored at - 20\u00b15 \u00b0C in the original container was accepted.  \n4.2 Drug Product  \nComirnaty is a white to off -white concentrate for dispersion for injection cont aining 225  \u00b5g/0.45 mL of \nmRNA embedded in lipid nanoparticles. The l ipid nanoparticles consist of four lipids: cholesterol, \nDSPC (1,2 -diste aroyl-sn-glycero -3-phosphocholine), ALC -0315 ((4 -hydroxybutyl) \nazanediyl)bis(hexane- 6,1-diyl)bis(2 -hexyldecanoate) and ALC -0159 (2 -[(polyethylene glycol) -2000] -\nN,N-ditetradecylacetamide).  \nThe d rug product is supplied as a sterile, preservative- free, multidose presentation. After dilution with \n1.8 mL of 0.9% sterile sodium chloride, at least 5 doses of 0.3 mL,  each contai ning 30 \u00b5g of drug \nsubstance , can be withdrawn. The applicant demonstrated that up to 6 doses dose may be extracted \nwhen low -dead volume syringes are used .  \nThe d rug product after dilution is intended for intramuscular administration.  \n The drug product as concentrate is formulated in an aqueous buffer containing potassium chloride, \npotassium dihydrogen phosphate, sodium chloride, disodium phosphate dihydrate and sucrose. All excipients, with the exception of DSPC and the novel excipients  ALC-0315 and ALC -0159, comply \nwith the European  Pharmacopoeia.  \n The d rug product is supplied in a 2 mL glass vial (glass type I) with a bromobutyl rubber stopper and \nan alumini um seal with flip -off plastic cap. The primary packaging materials comply with  the Ph. Eur. \nrequirements.  \n \nThe manufacturing process for the finished product consists of thawing and dilution of the drug \nsubstance, formation of lipid nanoparticles, buffer exchange, concentration and formulation,  followed \nby sterile filtration, asept ic filling into the final containers, inspection, labelling and freezing.  \n A detailed description of the manufacturing process development and process characteri sation \nstudies was provided,  and critical parameters were defined. The m anufacturing history , including \nprocess changes and transfer to commercial facilities , was sufficiently described. Comparability of the \nmaterial for emergency use and commercial supply with clinical batches has been demonstrated,  \nbased on the release testing and extended charac terisation studies.  \nThe m anufacturing process validation is ongoing. The data from several GMP batches were provided \nprior to approval. A full process validation report , including extended characteri sation and \ncomparability studies of the drug product , will be submitted as one of the conditions of temporary \nauthoris ation.  \nThe specification tests and acceptance criteria were provided and include a panel of analytical \nprocedures to confirm identity, composition, purity, potency and safety. Analytical methods  are \ndescribed,  and non -compendial methods have been validated in accordance with ICH requirements.  \n The drug product is stored at - 90 to - 60 \u00b0C in the original container. A preliminary shelf -life of 6 \nmonths has been granted based on the data available during the assessment.    \n \nSwissPAR  \n   9 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \nThe proposed in- use shelf -life for undiluted and thawed drug product of 5 days at 2- 8 \u00b0C, followed by \nup to 2 hours at up to 30  \u00b0C, was accepted.  \nDrug product after dilution with 0.9% sodium chloride can be held for up for 6 hours at 2 -30 \u00b0C. From \nthe microbiological stand point, the diluted product should be used as soon as possible.    \nExposure to light should be minimi sed.  \n \nThe manufacturing proc ess for the  drug substance and drug product incorporates  adequate control \nmeasures to prevent contamination and maintain control with regard to adventitious agent \ncontamination.  \n4.3 Quality Conclusions  \nFrom the quality perspective the data presented in the application support the conclusion that the manufacture of Comirnaty is robust and sufficiently controlled to yield the product of consistent quality.  \n   \n \nSwissPAR  \n   10 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n5 Nonclinical Aspects  \nPharmacodynamics / efficacy  \nBNT162b2 is a vaccine intended to prevent COVID -19, whi ch is caused by SARS -CoV-2. BNT162b2 \nis a nucleoside modified mRNA (modRNA) expressing trimeric full -length spike (S) protein with two \nproline mutations (P2) to lock the transmembrane protein in an antigenically optimal prefusion \nconformation. The modified mRNA contains a 5\u2019cap- structure and a poly(A) 3\u2019 -tail. The codons are \nhumanised and uridine is replaced by N1- methyl -pseudouridine to allow efficient translation in human \ncells. The vaccine is formulated in lipid nanoparticles (LNP s), which are  composed of 4 lipids: ALC -\n0315, ALC -0159, DSPC, and cholesterol. Other excipients in the formulation include sucrose, NaCl, \nKCL, Na 2HPO 4, and KH 2PO 4. The drug product is a preservative- free, sterile dispersion of RNA \nformulated in LNP s in an aqueous cryoprotectant buffer for intramuscular (IM) administration.  For \nmore details, see above (Quality Aspects).  \n \nIn cell culture  it was shown that , after uptake of the modRNA, the S protein is localised in the \nendoplasmic reticulum (ER) and on the surface of cells in the plasma membrane. Ultrastructural \nanalyses confirmed the prefusion conformation in 20.5% of the trimeric S protein.  \n \nAnimal studies were performed in mice and non -human primates (NHP s). In mice , the \nimmunogenicity of BNT162b2 was evaluated after sing le IM injections  of 0.2, 1 and 5 \u00b5 g of lipid -\nformulated modRNA/animal. BNT162b2 induced a humoral immune response characterised by a \nbalanced induction of S protein- specific IgG1 and IgG2 immunoglobulins binding to important S \nprotein domains such as the S 1 and the ACE2 receptor -binding domain. Neutralising \nimmunoglobulins were induced in a BNT162b2 -dose -dependent manner as measured by an S \nprotein- pseudotyped VSV virus -based neutralisation assay. The balanced IgG2/IgG1 ratio pointed to \na BNT162b2 -mediated Th1 immune response. The Th1 immune response was further characterised \nby an induction of Th1- specific cytokines in splenocytes such as  INF\u03b3 and IL- 2, but not Th2 -specific \ncytokines such as IL- 4, IL-5 and IL -13. INF\u03b3 was secreted by CD4+ and CD8+ T -cells. In all analysed \ncompartments of the immune system, BNT162b2 application mediated the increase and activation of \nTfh cells, a T- cell typ e supporting B cell responses.  No prime -boost regimen was applied, no old \nanimals were tested, and no long -term immunity data were generated in mice.  \n \nAn NHP  prime -boost study  with i.m. injection s of 30 or 100 \u00b5 g BNT162b2 on study days 0 and 21 \nwas perfor med in adult animals. No old animals were studied, and no long- term study was performed \nto assess long -term immunity. The prime- boost regimen induced an IgG humoral response with \nneutralising antibody titres of similar or higher range as compared to human convalescent plasma. \nThree weeks after boost, there was a trend showing a reduction in the neutralising antibody titres. The \navailable data with respect to the cell -mediated immunity point to a Th1 response as measured by a \nstrong induction of INF\u03b3  and only a low induction of IL- 4. No analysis was performed regarding the \ninnate immune responses.  \n An NHP  challenge study  was performed after prime- boost vaccination with BNT162b2 and animals \ninfected with 10\n6 PFU of the SARS- CoV-2 strain USA -WA1/2020. M acaques are a model for viral \ninfection,  but not a model for virus -induced pathogenicity, as animals show no clear signs of illness \nafter challenge SARS -CoV-2. Furthermore, the immune response of non -vaccinated animals against \nthe challenge virus reduces t he viral load by day 6. Therefore, only a short time window of 3 to 6 days \ncan be used to show differences between vaccinated and non- vaccinated animals. A fter prime -boost \nvaccination, the viral load in bronchoalveolar lavage (BAL), nasal and oropharyngeal  (OP) swabs was \nreduced as compared to controls. The maximum  viral load in controls was determined three days \nafter infection.  \n \nNo studies with respect to safety pharmacology  were conducted, which can be accepted based on \nthe absence of safety signals from  GLP toxicity studies.  \n  \n \nSwissPAR  \n   11 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n \nPharmacokinetics  \nStandard pharmacokinetic studies with respect to absorption, metabolism and excretion (ADME \nstudies) were not performed with modRNA. Detailed ADME studies are not usually required for \nvaccines by international agreement , and the lack of these data is acceptable due to the nature of the \nmRNA -LNP product.  \n \nThe metabolism of the modRNA was not investigated. It is estimated that the mRNA is degraded \nwithin the target cells within hours to a few days. From the four l ipid compounds, ALC-0315 and ALC-\n0159 were assessed. The other two lipids (distearoylphosphatidylcholine, cholesterol) are natural \nlipids that are metabolised in the same way as the endogenous counterparts. Following intravenous \ninjection, plasma concentra tions of ALC -0315 and ALC -0159 decreased rapidly, with an initial T 1\u20442 of \n1.6 and 1.7 hours, respectively. ALC -0315 and ALC -0159 were then cleared from plasma, resulting in \na terminal elimination t 1\u20442 of 139 and 72.7 hours , respectively. ALC-0315 and ALC -0159 were stable \nfor two hours in liver microsomes, S9 fractions and after incubation for four hours with hepatocytes. \nWhen incubated for longer time points in blood, liver S9 and liver hepatocytes, ALC -0315 was \nhydrolysed by de- esterification.  The estimate d percent of dose distributed to the liver  was ~60% \nfor ALC -0315 and ~20% for ALC -0159. The percent of dose excreted unchanged in f aeces  was \n~1% for ALC -0315 and ~50% for ALC -0159.  \n \nThe biodistribution  of lipid -mRNA particles was assessed in mice using various LNP -formulated \nmodRNA s encoding luciferase. After IM injection, luciferase activity was monitored in vivo  for 9 days. \nThe highest signals were detected at the injection site and,  6 hours after inj ection,  in the liver. The \nactivation of the innate immune system was also determined in the same studies in mice with the \nmRNA -LNP encoding luciferase by measuring several chemokines/cytokines. The mRNA -LNP \ninjection resulted in a transient induction of IL -6, MCP -1 and IP -10, indicating activation of \nmacrophages.  Following intramuscular administration of radiolabelled mRNA -LNP in rats , the highest \nconcentration was found at  the injection site. Outside the injection site, low levels of radioactivity were \ndetected in most tissues, with the highest  levels in the liver.  \n \n \nToxicity  \nThe toxicity of BNT162b2 was assessed in rats , with three weekly IM injections  at dose levels of 30 \nor 100 \u03bcg and a recovery phase of three weeks. There were no vaccine- related mortalities or gross \nclinical signs. Clinical findings included slightly reduced body weights and body weight gain and \nelevations in body temperatures. There  were no changes in food intake. There were no vaccine-\nrelated ophthalmologic or auditory alterations. None of the animals of any treatment group revealed \nany systemic changes in behaviour, external appearance, or consistency of faeces. Local reactions \nincluded thickening at injection sites , with reversible erythema and oedema development. The \nreactions were stronger after the second and third injections and resolved prior to the subsequent \ndosing. Microscopic findings confirmed a local inflammatory reaction associated with mixed \nmononuclear cell infiltration, variable fibrosis, myofib re degeneration and inflammation of the \nperineural tissue of the sciatic nerve, increased cellularity of germinal centres and increased plasma \ncells in the draining lymph nodes, increased cellularity of ha ematopoietic cells and germinal centres of \nthe spleen and increased cellularity of hematopoietic cells in the bone marrow. In addition, reversible \nvaccine- related vacuolation of periportal  hepatocytes was observed in the liver, with no evidence of \nliver injury. Liver enzymes (AST, ALP) were increased in vaccinated animals. Macroscopic analyses \nrevealed the local injection reactions (abnormal colour, abnormal consistency) transient enlargeme nts \nof draining lymph nodes associated with inflammation and enlarged spleens with increased \nhaematopoiesis. Haematological observations were reversible and included a transient reduction in \nreticulocytes, minimal decreases in RBC, HGB, HCT, sporadic small -magnitude decreases in \nplatelets, increases  in white blood cells (neutrophils, eosinophils, basophils, monocytes and large \nunstained cells) and changes in acute phase markers (higher alpha- 1 acid glycoprotein and alpha- 2- \n \nSwissPAR  \n   12 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \nmacroglobulin and fibrinogen and l ower albumin). In addition, a higher red cell distribution width, \nhigher globulin levels, and a lower albumin:globulin ratio were observed.  \n \nWith the exception of the microscopic injection site reaction , all findings were reversible. \nAdministration of thre e once -weekly doses of BNT162b2 elicited SARS -CoV-2 neutrali sing antibody \nresponses at the end of the dosing and recovery phases of the study.  \n \nNo genotoxicity  studies were performed. Based on the current scientific findings,  and by \ninternational agreement , this can be accepted, as neither the mRNA nor the lipids are expected to \nhave a genotoxic potential.  \n The developmental and reproductive toxicity  (DART) was evaluated in rats by IM injection of \nBNT162b2 (30 \u00b5g/dose) in female rats 21 and 14 days before m ating and on gestation days 9 and 20. \nNeutralising antibodies were measurable in female animals and in foetuses. There were no adverse \neffects on mating performance or fertility in F0 female rats or on embryo- foetal or postnatal survival, \ngrowth, or the development of the F1 offspring. It is not known whether the vaccine can be transferred \nvia placental transfer or with the milk during lactation.  \n \nNonclinical benefit risk assessment  \nIn nonclinical studies, BNT162b2 showed humoral and cellular immune stimulation towards a Th1 response. The vaccine induces neutralising antibodies that are able to control SARS- CoV-2 \namplification. Based on the pharmacokinetics, it can be assumed that mos t of the BNT162b2 stays \nlocally at the injection site. Outside the injection site, low levels of radioactivity were detected in most \ntissues, with the highest  levels in the liver.  This systemic distribution might be favourable for the \nimmune response. On t he other hand, it also poses a risk with respect to the development of \nunpredictable adverse events. The toxicity profile is acceptable. All local effects show a reversible tendency , and systemic effects are fully reversible within three weeks after the vaccine administration. \nConsidering the totality of data, it can be concluded that , in the light of the current pandemic, the \nbenefit of the vaccine outweighs the risk. The BNT162b2 vaccine can be approved from the preclinical perspective.  \n \n   \n \nSwissPAR  \n   13 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n6 Clinical and Cl inical Pharmacology Aspects  \n6.1 Clinical Pharmacology \nThe vaccine is based on the SARS -CoV-2 spike glycoprotein (S) antigen encoded by RNA and \nformulated in lipid nanoparticles (LNPs).   \nMechanism of Action  \nThe nucleoside- modified messenger RNA in the vaccine is formulated in lipid nanoparticles, which \nenable delivery of the RNA into host cells to allow expression of the SARS -CoV-2 S antigen. The \nvaccine elicits both neutrali sing antibody and cellular immune responses to the spike (S) antigen.  \n \nImmunogenicity  \nImmunogenicity data are available from two studies: the phase 1 study BNT162- 01 (First in Human, \nFIH), conducted in Germany since April 2020,  and phase 1 of the phase 1/2/3  study C4591001, \nstarted shortly afterwards  in the USA . Both studies are still ongoi ng.  \n \nIn both studies phase 1 was  designed to choose the optimal vaccine candidate and an appropriate \ndose and schedule for phase 2/3 of study C4591001, which is the pivotal efficacy and safety study.  \n For both phase 1 studies, immunogenicity data are avai lable for up to 1 month after the second dose.  \n \nSTUDY BNT -162-01 \nStudy BNT162- 01 is a multi -site, dose- escalation trial, initially investigating the safety and \nimmunogenicity of four prophylactic SARS -CoV-2 RNA vaccines. Healthy adults 18 to 55 years of age \nall received active vaccine. The protocol was later amended to allow inclusion of older adult \nparticipants up to 85 years of age. By  the time Comirnaty\u00ae had received its temporary authorisation \nby Swissmedic, safety and immunogenicity data were available for up to 28 days after dose t wo in \nadults 18 to 55 years of age. The study is ongoing, and subjects will be followed for immunogenicity  \nand safety for up to 162 days post -dose two. This will include adults aged 56 to 85 y ears.  \n \nThe final two vaccine candidates were BNT162b1 and BNT162 b2, and BNT162b2 was ultimately \nchosen, based on the overall humoral and cellular response as well as the reactogenicity profile (see \nsections 6.2 and 6.4). The results for the final vaccine candidate, BNT162b2, are presented here.  \n The dose levels tested for BNT162b2 were as follows: 1 \u03bcg, 3 \u03bcg, 10 \u03bcg, 20 \u03bcg, 30 \u03bc g (at the time of \ninterim study report preparation, data for the dose levels of 50 \u03bcg and 60 \u03bcg were not available).  \nDosage frequency: Two injections about 21 days  apart.  \n 12 subjects were planned for each dose level.  \n \nThe humoral immune response in healthy adults after dose 1 only or after both doses  1 and 2 was \ntested primarily by looking at functional antibody responses, fold increase in functional antibody \nGMTs, and the number of participants with seroconversion,  defined as a minimum of a 4-fold i ncrease \nin functional antibody GMTs compared to baseline.  \n \nThe cell-mediated immunity ( CMI) responses  (induced SARS -CoV-2 specific  CD4+ and CD8+ T -cell \nresponses, f unctionality and polari sation of IMP -induced SARS -CoV-2 specific T -cells as assessed by \nICS) were  also tested.  \n \nKey humoral and cellular immunity results are summarised below.  \n \nHumoral Immunity  \nFold increase from baseline in functional 50% SARS -CoV-2 neutrali sing antibody titres   \n(VN 50) \u2013 IMM \nIMM = Immunogenicity set; VN50 = 50% SARS -CoV-2 neutrali sing antibody titres   \n \nSwissPAR  \n   14 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n \nGeometric means fold increase (GMFI) from baseline in VN50 titre  with 95% confidence intervals are shown for BNT162b2 \ndose levels. Arrowheads indicate baseline (dose 1, Day 1) and dose 2 (Day 22). The dotted horizontal line represents the \nthreshold for seroconversion (fold increase \u22654).  \n \nOne can see that on Day 29 (= 7 days after the second dose of BNT162b2), virus neutrali sing GMTs \nwere highest for the 30 \u03bcg dose level, although by day 43 they had diminished somewhat and were \nsimilar to the 10 \u00b5g level.  \n \nDay 43 virus neutrali sing GMTs were 0.3- fold (1 \u03bcg dose) to 1.7 -fold (30 \u03bcg  dose) those of a COVID -\n19 human convalescent sera (HCS) panel com prised of 38 human COVID -19 HCS. This panel \nincluded individuals  aged 18 to 83 y ears, at least 14 days after confirmed diagnosis (symptomatic \ndisease for 35 of the 38 sera obt ained at a time when the individuals were asymptomatic). This \nconfirmed that the 30 \u03bcg dose of BNT162b2 induces virus neutrali sing GMTs which are, on average, \nhigher than  those induced by a natural infection.  \n \nFrequency of subjects with SARS -CoV-2 GMT ser oconversion: BNT162b2 IMM  \nSeroconversion is defined as a minimum of 4- fold increase in  functional antibody response compared \nto baseline.  The frequency of younger adults aged 18 to 55 years with seroconversion is displayed \nbelow:  \n \nGMT = geometric mean titre ; IMM = Immunogenicity set.  \nNote: At the cut -off date for this report, only limited data for the 20 \u03bcg dose level were  available (7 sera evaluable for Day 29, \n4 sera evaluable for Day 43).  \n \n \nSwissPAR  \n   15 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n \nIn summary, at least for the 10 \u03bcg   and 30  \u03bcg  doses, partici pants vaccinated with two doses of \nBNT162b2 showed both neutralising antibody titres  that were higher than human convalescent sera \nand at least a 4 -fold increase in functional antibody response compared to baseline. In the absence of \nknown correlates of protection against SARS -CoV-2, this was deemed acceptable by both the \ncompany and by Swissmedic.  \n \nCellular Immunity  \n \nSARS -CoV-2-specific CD4+ and C D8+ T -cell responses \nEvaluable CD4+ and CD8+ T -cell response data (ELISpot data) were available from 39 participants \ndosed with 1, 3, 10, 20, or 30 \u03bcg BNT162b2.  \n \nBNT162b2 induced strong SARS -CoV-2 S protein -specific CD4+ and CD8+ T -cell responses in all , or \nalmost all , the dosed participants (39 of 39 [100%] and 35 of 39 [89.7%]), respectively. These T- cell \nresponses were directed against different parts of the antigen,  including epitopes in the RBD, \nindicating the induction of multi -epitopic responses by B NT162b2.  \n Dosing twice with BNT162b2 led to a substantial increase in incidence and magnitude of T -cell \nresponses, especially for dose levels of 10 \u03bcg or higher.  \n \nFunctional and pro- inflammatory CD4+/CD8+ T -cell responses,\n including Th1 (IFN\u03b3 and IL- 2) an d \nTh2 (IL -4) cytokine profile of T -cells specific to S or RBD of SARS -CoV-2 were assessed by ICS. De \nnovo induction of SARS -CoV-2 S or RBD protein  directed T- cells was confirmed. INF \u03b3-producing CD4 \nand CD8 T -cells against SARS -CoV-2 S or RBD were not detected at baseline in participants and \nwere induced robustly by BNT162b2. No clear dose dependency was observed.  \n \nThe results confirm that the Th1 response is greater than the Th2 response. Th1 / Th2 > 1 is desired, \nbecause a Th2 response may be associated with vaccine- associated enhanced respiratory disease.  \n \nThe data presented in this first -in-human study were obtained from healthy younger adults (aged \nbetween 18 and 55 years). Adults  aged between 56 and 85 years of age have already been enrolled \nin the study , but the results will b e reported at a later date , in any case before a full marketing \nauthorisation is granted.  Follow -up data up to six months will be available for both age groups.  \n  \n \nPHASE 1/2/3 STUDY C4591001 \nStudy C4591001 is a Phase 1/2 /3, Placebo- Controlled, Randomis ed, Observer -Blind, Dose -Finding \nStudy to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS -COV -2 RNA \nVaccine.  \n \nThis study is also ongoing.  \nSubject First Visit: 29 April 2020 Data Cut -off dates:  \n\u2022 24 August 2020 (Phase 1 safety and immunogenicity data through 1 month after Dose 2)  \n\u2022 02 September 2020 (Phase 2 safety data 7 days after Dose 2 only)  \n\u2022 06 October 2020  (Phase 2/3 safety data 1 month after Dose 2 for the first 6610 participants, and \navailable safety data for all 36,855 participants)  \n\u2022 04 November 2020 (Phase 2/3 first interim analysis for efficacy at 94 cases)  \n\u2022 14 November 2020 (Phase 2/3 final analysis  for efficacy at 178 cases, safety data 1 month after \nDose 2 for 37,586 participants with a median of at least 2 months of follow -up, and available safety \ndata for all 43,252 participants).  \n Study C4591001 was started as a Phase 1/2 study in adults in the US, and was subsequently \nexpanded into a global Phase 2/3 study. 44,822 subjects were enrolled, and 43,386 subjects were  \n \nSwissPAR  \n   16 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \nrandomised at 153 centres in 6 countries worldwide, including: United States (131 centres, 33,068 \nsubjects), Argentina (1 site, 5,776 s ubjects), Brazil (2 sites, 2,900 subjects), Turkey (9 sites, 342 \nsubjects), South Africa (4 sites, 800 subjects) and Germany (6 sites, 500 subjects).  \n The study was also later amended to include older adolescents 16 to 17 years of age, then later \namended t o include younger adolescents 12 to 15 years of age. For  the current, temporary \nauthoris ation, only participants 16 and over were considered in the interim and final (primary efficacy \nendpoint) interim analyses.  \n \nA last protocol amendment, dated 01 December 2020, was submitted by the company around the \ntime that Swissmedic granted a temporary authorisation for Comirnaty\u00ae. The reason for the amendment was that , after emergency and/or temporary authorisations were granted in countries with \nstudy centres, it would no longer be feasible to keep all participants in the study. The amendment \nadded the possibility of administering BNT162b2 to participants who originally received placebo, \nfollowing completion of an  active blinded safety surveillance period of maximu m 6 months after dose \ntwo.  \n A final study report from study C4591001 is planned for 2023.  \n \nPhase 1 Immunogenicity  Endpoints  \nIn Phase 1, two age groups were studied separately, younger participants (18 to 55 years of age) and \nolder participants (65 to 85 y ears of age). The study population included healthy male and female \nparticipants. The immunogenicity objectives were to describe the immune response in healthy adults \nafter dose 1 only or after both doses  1 and 2 (two injections about  21 days apart). The doses tested \nwere 10, 20 and 30 micrograms for both age groups.  \n \nFor each dose group of 12 participants receiving one of the two vaccine candidates, three additional \nparticipants received a placebo vaccine (randomisation ratio of 4:1). The p lacebo consisted of normal \nsaline.  \n \nHumoral immunogenicity was assessed at Day 1 (before Dose 1) and 7 days after Dose 1 , at Day 21 \n(before Dose 2) and 7 days, 14 days, and 1 month after Dose 2. Data were summarised for each \ndose level and age group.  \n \nBNT162b2 SARS- CoV-2 Neutrali sing Titres  \nIn the younger age group, SARS -CoV-2 50% neutrali sing GMTs increased by Day 21 after Dose 1 \nand were substantially increased 7 days after Dose 2 (Day 28) of BNT162b2.  \nSimilar trends were generally observed in the older age gr oup, with higher GMTs observed in the 30 \n\u03bcg dose groups compared to the 20 \u03bcg and 10 \u03bcg dose groups. In the older age group, SARS -CoV-2 \n50% neutrali sing GMTs were generally lower than the GMTs in the younger age group.  \n \nPhase 2 Immunogenicity Endpoints  \n \nThe phase 2 part of the study was comprised of the first 360 participants enrolled  (1:1 \nrandomi sation between BNT162b2 and placebo, stratified by age groups [18 to 55 years and >55 to \n85 years] with approximately 50% in each age stratum) , and was designed to assess safety data \nthrough 7 days after d ose 2 and immunogenic ity data through 1 month after dose 2. In Phase 2, \nimmunogenicity  was assessed at Day 1 (before dose 1) and 1 month after dose 2.  \n  \nImmunogenicity results from the 360 participants in Phase 2  of the study demonstrated that \nBNT162b2 at 30 \u00b5g elicited SARS -CoV-2 neutrali sation and S1 -binding IgG antibody responses at 1 \nmonth after dose 2 similar to those previously observed in phase 1 of the study. Notably, SARS -\nCoV-2 neutrali sing titres  were hi gher in the younger age cohort compared with the older age cohort.  \n  \n \nSwissPAR  \n   17 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \nS1-binding GMCs were generally also higher in the younger age cohort compared to the older age \ncohort, again concordant with observations in the Phase 1 portion of the study.  \n \nPhase 3 Immu nogenicity Endpoints  \n \nIn the phase 3 part of the study, immunogenicity is a secondary  (12 to 15- year-olds compared with \n16 to 25- year-olds) and exploratory endpoint. These data will be reported by the company at a later \ndate and were not included in the interim study report .  \nFurther evaluation of immunogenicity is scheduled for  months  6, 12 and 24 following dose 2.  \nThe exploratory immunogenicity assessments are therefore planned at time points up to 24 months.  \n \nOne of the planned exploratory endpoints includes the description of the serological responses to the \nBNT vaccine candidate in cases of:  \n\uf0b7 Confirmed COVID -19 \n\uf0b7 Confirmed severe COVID -19 \n\uf0b7 SARS- CoV-2 infection without confirmed COVID -19 \nThis might help in the determination of correlates of protection.  \n \nImmune responses induced by the vaccine against emerging circulating strains of SARS -CoV-\n2 will also be investigated. Effectiveness studies included in the RMP will be important to \nunderstand the performance of the vacci ne in case of e.g. mutating variants.  \n \nEfficient neutrali sation of spike protein mutants including RBD sequence variants was observed with \nsera from vaccine- immuni sed study BNT162 -01 participants, demonstrating the neutrali sation breadth \nof vaccine- elicite d polyclonal antibodies. It may be important to consider this aspect when facing \nemerging variants with mutations in the spike proteins, e.g. the UK variant, as the vaccine might still be able to confer sufficient cross -neutralisation.  \n \n6.2 Dose Finding and Do se Recommendation  \nThe choice and dose of vaccine candidate were  based on the results of the two clinical phase 1 trials \npresented above (study BNT -162-01 and phase 1 of study C4591001) and took into account safety, \ntolerability, and immunogenicity. For safety data see section 6.4  below.  \n \nChoice of Vaccine C andidate  \nThe neutralising antibody responses between the two vaccine candidates were considered similar. \nFor both BNT162b1 and BNT162b2, the S1-  and RBD -binding IgG kinetics were comparable with  the \nkinetics of neutrali sing antibodies, with lower IgG concentrations  in the older age group than in the \nyounger age group.  \n For the 30 \u03bcg dose cohort vaccinated with BNT162b2, however, CD4 and CD8 cytokine responses \nshowed the same intensity in adults and older adults, whereas for the 30 \u03bcg dose cohort vaccinated \nwith BNT1 62b1, RBD -specific IL -2-producing CD4+ and CD8+ T cells were reduced in older adults.  \n \nAlso in older adults, the vaccine candidate BNT162b2 had a reactogenicity profile in clinical trials that \nseemed more favourable than that observed with BNT162b1 (see section 6.4).  \n Thus,  BNT162b2 was eventually chosen over BNT162b1 to proceed to the phase 2 and 3 parts of \nstudy C4591001 as it provided the optimum combination of a favourable reactogenicity profile and a \nrobust immune response likely to afford protection against COVID -19 in younger and older adults.  \n \nBenefits of Second D ose \nThe immune  responses in terms of neutrali sing antibody responses clearly demonstrated that two \ndoses resulted in increased geometric mean titres (GMTs) compared to responses after only the first  \n \nSwissPAR  \n   18 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \ndose. Thus,  in the absence of a serological correlate of protection, these data supported the need for \ntwo doses in adults. The responses to the vaccines w ere higher compared to a pool of human \nconvalescent sera in study BNT162- 001. \n \nChoice of the 30  \u03bcg Dose Level  \nThe S1 - and RBD -binding IgG kinetics were comparable with  the kinetics of neutrali sing antibodies, \nwith lower IgG concentrations in the older age group than in the younger age group.  \nThe responses were numerically higher in higher dose groups compared to lower doses but did not \nsubstantially differ between 10 ug and 30  ug. However, S1 -IgG antibody -binding concentrations after \nBNT162b2 favoured the s election of the 30 \u03bcg dose level. When selecting the dose level for Phase \n2/3, the major driver was the need to maximi se SARS -CoV-2 neutrali sing antibody responses in the \nolder age group, who are at the highest risk of severe disease.  \n \n6.3 Efficacy  \nPivotal S tudy C4591001: Phase 2/3 of the 1/2/3 Study  \nThe phase 2/3 evaluation part of pivotal Study C4591001 phases 1/2/3 started on 27 July 2020, \nusing BNT162b2 at the 30 \u03bcg dose level. The 360 phase 2 participants are included in the efficacy \nevaluation of the phase 2/3 study.  \n \nPhases 2 and 3 of study C4591001 constituted the pivotal efficacy  and safety  study. It was a placebo-\ncontrolled, randomis ed, observer -blind1, event -based study. Two interim efficacy analyses were \ncarried out once a certain number of symptomatic and PCR positive COVID -19 cases had occurred in \nthe study (event -based study).  \n \nFirst Interim Analysis for Efficacy  \nThe first interim analysis was based on 94 total cases of COVID -19 occurring at least seven days \nafter the second dose. The cut -off date was 04 November 2020.  \n \nThis first interim analysis met the minimal statistical analysis plan requirements for vaccine efficacy, \nand, with the final interim analysis (see below), the minimal median safety follow -up of two months \nfollowing the second dose was also met.  \n \nAmong participants included in the evaluable efficacy population, 32,279 participants (16,061 in the \nBNT162b2 group and 16,218 in the placebo group) did not have evidence of infection with SARS -\nCoV-2 through 7 days after the second dose. From that point in time onward, 4 COVID -19 cases  were  \nreported in the BNT162b2 group compared to 90 COVID -19 cases reported in the placebo group. \nThese data give an estimated vaccine eff icacy of 95.5% for BNT162b2.  \n \nFinal Interim Analysis for Efficacy  \nOn 09 December 2020, the company submitted a final interim efficacy report dated 03 December \n2020, with a data cut -off date of 14 November 2020. This \u201cFinal Analysis Interim Report\u201d was bas ed \non 178 cases of COVID -19 (169 in the placebo group and 9 in the vaccine group) occurring at least 7 \ndays after the second dose.  \n \n44,822 subjects had been enrolled and 43,386 subjects had been randomised at 153 centres, in 6 \ncountries worldwide, including: United States (131 centres, 33,068 subjects), Argentina (1 site, 5,776 \nsubjects), Brazil (2 sites, 2,900 subjects), Turkey (9 sites, 342 subjects), South Africa (4 sites, 800 \nsubjects) and Germany (6 sites, 500 subjects). The evaluable efficacy populati on included all \neligible randomised participants who received all vaccinations as randomis ed, with Dose 2 received \n                                                \n1 The study is observer -blinded, as the physical appearance of the investigational vaccine candidates and the placebo may differ.  The \nparticipant, investigator, study coordinator, and other site staff are blinded. At the study site, only the dispensers/admini strators are \nunblinded \n  \n \nSwissPAR  \n   19 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \nwithin the predefined window of 19 -42 days after dose 1, and who had no other important protocol \ndeviations as determined by the clini cian on or before 7 days after dose 2. This was the primary \nanalysis population for all efficacy analyses.  Additional analyses based on the all -available \nefficacy populations, including all randomis ed participants who completed one and two vaccination \ndoses respectively, were also performed.  \n \nThere were two parts to the primary efficacy endpoint:  \n\u2022 First primary efficacy endpoint : To evaluate the efficacy of prophylactic BNT162b2 against \nconfirmed COVID -19 occurring from 7 days after the second dose in participants  without \nevidence of infection before vaccination.  \n\u2022 Second primary efficacy endpoint: To evaluate the efficacy of prophylactic BNT162b2 \nagainst confirmed COVID -19 occurring from 7 days after the second dose in participants with \nand without evidence of SARS- CoV-2 infection before vaccination.  \n \nFirst primary efficacy endpoint:  \n \nThe f irst primary efficacy endpoint included 18 ,198 vaccine group and 18, 325 placebo group subjects.  \nIn the first primary analysis, the efficacy of COVID -19 mRNA vaccine from 7 days after Dose 2 was \nmeasured in participants without evidence of prior infection with SARS -CoV-2. The results showed a \n95.0% (95% confidence interval of 90.0% to 97.9%) vaccine efficacy in participants 16 years of age \nand older.  \nDemographics table (population for the first primary efficacy endpoint) a\na. All eligible randomised participants who receive all vaccinations as randomised within the predefined window, have no \nother important protocol deviations as determined by the clinician, and have no evidence of SARS -CoV-2 infection prior to \n7 days after Dose 2.  \nb. Includes multiracial and not reported.  \nc. Number of participants who have 1 or more comorbidities that increase the risk of severe COVID -19 disease  \n\u2212 Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic pulmonary fibrosis , and cystic fibrosis) or \nmoderate to severe asthma  \n\u2212 Significant cardiac disease (e.g., heart failure, coronary artery disease, congenital heart disease, cardiomyopathies, and \npulmonary hypertension)  \n\u2212 Obesity (body mass index \u2265 30 kg/m 2)  \n\u2212 Diabetes (T ype 1, Type 2 or gestational)  \n\u2212 Liver disease  \n\u2212 Human Immunodeficiency Virus (HIV) infection (not included in the efficacy evaluation)  \n \nAs can be seen from this demographics table, extremely few persons over 85 years of age were \nincluded in the study (five individuals only were vaccinated and five received placebo), and only 4.4% \nof the study population was between 75 and 85 years of age. This explains the very large confidence \nintervals around the efficacy results and therefore the uncertainty of the results in persons over 75 \nyears of age (see table below) . \n \nVaccine efficacy  table \u2013 First COVID -19 occurrence from 7 days after Dose 2, by age subgroup \u2013  \nparticipants without evidence of infection prior to 7 days after Dose 2 \u2013  evaluable efficacy (7 days)  \npopulation:  \n  \n \nSwissPAR  \n   20 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n \nNote: Confirmed cases were determined by Reverse Transcription -Polymerase Chain Reaction (RT -PCR) and at least 1 \nsymptom consistent with COVID -19 [*Case definition: (at least 1 of) fever, new or increased cough, new or increased \nshortness o f breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhoea or vomiting.]  \n* Participants who had no serological or virological evidence (prior to 7 days after receipt of the last dose) of past SARS -\nCoV -2 infection (i .e., N -binding antibody [serum] negative at Visit 1 and SARS -CoV -2 not detected by nucleic acid \namplification tests (NAAT) [nasal swab] at Visits 1 and 2), and had negative NAAT (nasal swab) at any unscheduled visit \nprior to 7 days after Dose 2 were includ ed in the analysis.  \na. N = number of participants in the specified group.  \nb. n1 = Number of participants meeting the endpoint definition.  \nc. Total surveillance time in 1000 person -years for the given endpoint across all subjects within each group at ris k for the \nendpoint. Time period for COVID -19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.  \nd. n2 = Number of subjects at risk for the endpoint.  \ne. No confirmed cases were identified in participants 12 to 15 years of age.   \nf. Confidence interval (CI) for vaccine efficacy is derived based on the Clopper and Pearson method adjusted to the \nsurveillance time. CI not adjusted for multiplicity.  \n \nSecond primary  efficacy endpoint :  \n In the second primary analysis, efficacy of COVID -19 mRNA Vaccine from 7 days after Dose 2 was \nmeasured in participants with or without evidence of prior infection with SARS -CoV-2. The results \nshowed a 94.6% (95% confidence interval of 89.9% to 97.3%) vaccine efficacy in participants 16 \nyears of age and older.  \n \n \n \nSwissPAR  \n   21 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n \n \n Secondary endpoints  \n \nOne of the most important secondary endpoints was the prevention of severe COVID -19 cases.   \n \nVaccine Efficacy \u2013  First Severe COVID -19 Occurrence From 7 Days After Dose 2 \u2013  Subjects Without Evidence of \nInfection Prior to 7 Days After Dose 2 \u2013 Evaluable Efficacy (7 Days) Population  \n \n \n \nSwissPAR  \n   22 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n \n \nAs the number of cases was very low, only numerical trends can be seen. As defined in the protocol \n(cases occurring after day 7 following dose two ), a secondary endpoint, there were 3 cases in the \nplacebo group and 1 case in the vaccine group. This corresponds to a 66.4% vaccine efficacy (95% \nconfidence interval of -124.8; 96.3).  The power of the study did not allow for a statistically significant \nresult.  \n \nCounting all severe COVID -19 cases occurring after dose 1 (thus including the 4 cases mentioned in \nthe previous paragraph) , there was a total of one case in the vaccine group and 9 cases in the \nplacebo group.  \nAll confirmed cases of COVID -19 after dose 1  \nAn analysis of the cases occurring from dose 1 and until dose 2 or 1 week after dose 2 provides \ninformation on the onset of protection.  \nThe table below lists all reports of COVID -19 with onset at any time after Dose 1 (all participants in the \nall-availabl e efficacy population, regardless of evidence of infection before or during the vaccination \nregimen).  \nAmong these participants, 50 cases of COVID -19 occurred after Dose 1 in the BNT162b2 group \ncompared to 275 cases in the placebo group. Notably, in the BN T162b2 group, most cases occurred \nbefore Dose 2.  \n \n \n  \n \n \nSwissPAR  \n   23 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \nVaccine Efficacy \u2013 First COVID -19 Occurrence After Dose 1 \u2013 Dose 1 All - Available Efficacy \nPopulation  \n    \nThe table above shows that the first dose offers partial protection, especially starting 14 days after dose \none. However, maxim um protection only occurs after 7 days have elapsed following dose 2. S ince \nmaxim um immunogenicity is seen after dose two, the duration of the immunogenicity observed after \ndose one may be shorter than that observed after dose two. It is also important to note that , even though \nthe efficacy analyses included participants who received their second vaccination within 19 to 42 days after their first vaccination, the majority (93.1%) of vaccine recipients received the second dose 19 days to 23 days after the first dose. \n \nDuration of follow -up \nThe primary analysis of efficacy was conducted when the pre- defined number of 164 COVID -19 \ncases had occurred. This corresponds to about 1.5 months of median follow -up time after completion \nof the full vaccination regimen. Therefore, available efficacy data are limited in terms of follow -up \nduration, and the efficacy of the vaccine over longer periods remains unknown. Data are expected to \nbecome available post -authorisation.  \n \n6.4 Safety  \nOverall Safety Database  \n For safety, the median follow -up time was two months after dose two (phase 2/3 of study C4591001). \n At the cut -off date of 14 November 2020, the longest follow -up time available was 12- 13 weeks after \nDose 2 (N=780: N=382 BNT162b2 and N=398 placebo).  \n Overall, study C4591001 enrolled Phase 2/3 participants (N=43,448) that received at least one dose of BN T162b2 (N=21,720) or placebo (N=21,728), regardless of the duration of follow -up. \n The safety database consisted of:  \n\u2022 Study BNT162- 01 (N=60 any dose of BNT162b2; N=12 BNT162b2 30  \u00b5g; placebo N=0).  \n \n \nSwissPAR  \n   24 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n\u2022 Phase 1 of study C4591001 (N=72 any dose of BNT162b2; N=12 B NT162b2 30 \u00b5g; placebo \nN=18).  \n\u2022 Phase 2/3 participants with a follow -up \u2265 2 months after Dose 2 (N=19,037) of either \nBNT162b2 (N=9531) or placebo (N=9536).  \n\u2022 All enrolled Phase 2/3 participants (N=43,448) that received at least one dose of BNT162b2 \n(N=21,720)  or placebo (N=21,728), regardless of  the duration of follow -up.  \n\u2022 Phase 2/3 participants (N=37,706) randomised before 9 October 2020 who received BNT162b2 (N=18,860) or placebo (N=18,846). These subjects had a median follow -up time of \n2 months after Dose 2  (at least 1 month after dose 2). Of these, 1,148 subjects had a positive \nSARS- CoV-2 baseline status (vaccinated N=558; placebo N=590).  \n \nReactogenicity was evaluated based on a subset of subjects in the Phase 2/3 study, i.e. 8,183 \n(N=4,093 BNT162b2; N=4,090 placebo), who reported on local reactions, systemic events, and \nantipyretic/pain medication usage for 7 days after each dose in  an e-diary.  \n \nAdverse Events  \nThe adverse event (AE) profile did not suggest any serious safety concerns. The incidence of se rious \nadverse events (SAEs) and deaths occurring during the study were low and similar between the two \ngroups. There were two deaths in the BNT162b2 group and four in the placebo group, none due to \nCOVID -19 or to the study intervention. The incidence of di scontinuations due to AEs was similar \nbetween the BNT162b2 and the placebo groups.  \n \nAt the time of the analysis of Study C4591001, a total of 19,067 (9,531 Comirnaty and 9,536 placebo) participants 16 years of age or older were evaluated for safety for at  least 2 months after the second \ndose of Comirnaty. This included a total of 10,727 (5,350 Comirnaty and 5,377 placebo) participants \n16 to 55 years of age and a total of 8,340 (4,181 Comirnaty and 4,159 placebo) participants 56 years \nand older.  \n \nThe most frequent adverse reactions were injection site pain (> 80%), fatigue (> 60%), headache (> \n50%), myalgia and chills (> 30%), arthralgia (> 20%), pyrexia and injection site swelling (> 10%). \nOther reactogenicity events included pain in extremity, injection s ite redness, malaise, injection site \npruritus, lymphadenopathy, insomnia, and nausea. All reactions were usually mild or moderate in \nintensity and resolved within a few days after vaccination. A slightly lower frequency of reactogenicity events was associated with greater age. The frequenc ies of headache, fatigue and fever were  higher \nafter Dose 2 in both age groups.  \n Four participants in the vaccine group (frequency category \u201cRare\u201d (\u2265 1/10,000 to < 1/1,000) reported \nan event of acute peripheral facial paralysis (or palsy) . Onset was Day 37 after Dose 1 and Days 3, 9, \nand 48 after Dose 2. No cases of acute peripheral facial paralysis (or palsy) were reported in the \nplacebo group.  \n \nCases of hypersensitivity and anaphylaxis have been identified post -marke ting. A waiting time post -\nvaccination of at least 15 minutes has been established in each vaccination centre.  \n \nThere were no clinically meaningful differences by age group, baseline SARS -CoV-2 status, ethnicity, \nrace, or sex.  \n \nLaboratory Results  \nLaboratory results are available for the two Phase 1 studies. Except for a minor transient decrease in \nthe lymphocyte count observed for some of the subjects, no abnormal lab results were reported from \nthe Phase 1 studies.  \n   \n \nSwissPAR  \n   25 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \nReactogenicity  \n \nAvailable r eactogenicity data were based on the 360 participants of the phase 2 of trial C4591001:  \n \nSubjects Reporting Systemic Events, by Maximum Severity, Within 7 Days After Each Dose, \nAge Group 18- 55 Years \u2013  Phase 2 \u2013  Safety Population  \n \n \n  \nSubjects Reporting Systemic Events, by Maximum Severity, Within 7 Days After Each Dose, Age Group 56- 85 Years \u2013  Phase 2 \u2013  Safety Population  \n \n \n \nSwissPAR  \n   26 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n \n \n \nOverall, it is worth noting that reactogenicity events may be more severe after the second dose and that the degree of severity may, in a small percentage of cases, reach grade 3 or 4.  \n \n6.5 Final Clinical and Clinical Pharmacology Benefit Risk Assessment  \nBenefit  \nA vaccine efficacy of 95.0% (with 95% CI of 90% to 97.9%) was demonstrated for Comirnaty in a pre-\ndefined primary analysis (symptomatic cases of COVID -19 from seven days onward after second \ndose in participants without evidence of prior infection). The lower limit of 90.0% for the 95% CI for the \nprimary endpoint exceeded the pre -specified 30% lower margin established by the WHO and FDA.  \n \nA vaccine efficacy (VE) of 95.0% shows a very high degree of protection against COVID -19 and thus \na highly significant benefit of vaccination. It is likely that the vaccine also protects against severe COVID -19 although, because of a very low number of severe cases, the power of the study did not \nallow any statistical conclusions to be drawn.  \n A vaccine efficacy of 95% means that if 100 unvaccinated persons are ill with COVID -19, had they \nbeen vaccinated only 5 instead of 100 would have fallen  ill. Vaccine efficacy is the relative reduction \nin the risk: whatever a person\u2019s risk was before, it is reduced by 95% by the vaccine. It does NOT mean there is a 5% chance of getting COVID -19 if vaccinated. The risk of infection will depend on \nvaccination status, prevalence of the disease in the population, precautionary measures put in place \nand individual behaviour.  \n \nUncertainties and R isks \nUncertainties at the time Swissmedic granted a temporary authori sation included:  \n\u2022 The median follow -up after completion of the full vaccination regimen was 1.5 months. \nAvailable efficacy data are therefore limited in term s of follow -up duration, and the efficacy of \nthe vaccine over a longer time (duration of protection) remains unknown. More data are \nexpected t o become available post -authorisation.  \n \n \nSwissPAR  \n   27 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n\u2022 As COVID -19 vaccines are becoming available in the form of EUAs or conditional / temporary \napprovals in different countries, several phase 3 study participants are likely to quit the study \nand/or to want to break the blind in order to get the vaccine. Moreover, ac cording to study \namendment 10, all study participants will be unblinded 6 months after the second dose and \nthose in the placebo group will receive vaccine. This will make an efficacy and safety follow -up \nwith full study integrity impossible.  \n\u2022 The percentage of study subjects from certain subgroups is low  in view of the targeted \npopulation at risk for severe COVID : only about 25% of participants are over 65 years of age, \nand only about 20% have comorbidities.   \n\u2022 In the 75 -85 years and >85 years age groups, 837 and 5 participants respectively had been \nvaccinated with BNT162b2 (Dose 2 all -available efficacy). There are therefore not enough \nparticipants over 85 years of age to provide interpretable data for this age group.  \nNevertheless , the vaccine efficacy for persons over 65 overall is 94.7% (66.7%, 99.9%).  \n\u2022 The design of the study did not test for asymptomatic infections in vaccine recipients or the \npotential spread to contacts.  \n\u2022 Persistence of immunogenicity is unknown.  \n\u2022 The correlates of protection (specific imm unogenic responses that are particularly protective or \nnot protective of infection) have not been elucidated to date .   \n\u2022 There are no long- term data on rare, unexpected risks that may appear with time or as more \npeople get vaccinated.  \n\u2022 As seasonal influenza vaccines and other vaccines were not given concurrently  with the \nCOVID -19 vaccine, there are no data on the possibility of simultaneous vaccinations with other \ntypes of vaccines.  \n\u2022 Potential interactions between vaccine and medicines have not been studied.   \n\u2022 Protection after only one dose,  as well as the need for a second dose in previously infected \npersons , have not been tested.  \n\u2022 No data,  or very limited data,  are available on pregnant and lactating women, \nimmunocompromised persons, and paediatric subjects.  \n \nBenefit / Risk A ssessment  \n \nComirnaty was the first COVID -19 vaccine to receive a temporary marketing authorisation in \nSwitzerland.  \n The pandemic situation as described above under \u201cMedical Context\u201d and the vaccine\u2019s high efficacy \nfor protection against t he development of COVID -19 symptoms, together with an acceptable safety \nprofile, justified an early, temporary authorisation.  The risk reduction benefit clearly exceeds the \npotential safety risks. Additional and longer -term data are being collected with a  view to definitive \nauthorisation. Post -marketing data are also being gathered under the overview of regulatory \nauthorities (such as FDA, EMA, Health Canada, MHRA, Swissmedic) using established database  \nnetworks, thus guaranteeing adequate surveillance of efficacy and safety over the long term. Risk \nminimisation activities and safety studies are ongoing (see the RMP summary on the Swissmedic \nwebsite).  \n \nIn view of the rolling submission procedure and temporary authorisation in accordance with Art. 9a \nTPA,  the Swiss prescribing information will be updated as needed.  \n \nSee www.swissmedicinfo.ch\n for the latest ver sion.  \n \n6.6 Approved Indication and Dosage  \nSee information for healthcare professionals in the A ppendix.  For latest version, see \nwww.swissmedicinfo.ch .  \n   \n \nSwissPAR  \n   28 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n7 Risk Management Plan Summary  \nThe RMP summaries contain information on the medicinal products\u2032 safety profiles and explain the \nmeasures that are taken in order to further investigate and monitor  the risks as well as to prevent or \nminimise them.  \nThe RMP summaries are published separatel y on the Swissmedic website. Marketing A uthorisation \nHolders are responsible for the accuracy and correctness of the content of the published RMP \nsummaries. As the RMPs are international documents, their summaries might differ from the content \nin the infor mation for healthcare professionals / product information approved and published in \nSwitzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss \nauthorisations . \n   \n \nSwissPAR  \n   29 / 29 \nSwissmedic  \u2022   Hallerstrasse 7  \u2022  3012 Berne  \u2022  www.swissmedic.ch  \u2022  Tel. +41 58 462 02 11  \u2022  Fax +41 58 462 02 12 \n8 Appendix  \n8.1 Approved Information for Healthcare Profe ssionals  \nPlease be aware that the following version of the i nformation for healthcare professionals relating to \nComirnaty  concentrate for dispersion for injection was the version approved at the time of the \nSwissPAR  publication. This information for healthcare professionals may have been updated since \nthe SwissPAR was published.  \n \nPlease note that the reference document, which is  valid and relevant for the effective and safe use of \nmedicinal products in Switzerland, is  the information for healthcare pr ofessionals  approved and \nauthorised by Swissmedic  (see www.swissmedicinfo.c h). \n \nNote:  \nOnly the i nformation for healthcare professionals approved in one of the official Swiss language s is \nbinding and legally valid.   \n \nFachinformation f\u00fcr Humanarzneimittel  \n   1 / 21 \u25bc Dieses Arzneimittel unterliegt einer zus\u00e4tzlichen \u00dcberwachung. Dies erm\u00f6glicht eine schnelle \nIdentifizierung neuer Erkenntnisse \u00fcber die Sicherheit. Angeh\u00f6rige von Gesundheitsberufen sind  \naufgefordert, den Verdacht einer neuen oder schwerwiegenden Nebenwirkung zu melden. Hinweise \nzur Meldung von Nebenwirkungen, siehe Rubrik \u00abUnerw\u00fcnschte Wirkungen\u00bb.  \nDie vorliegende Produktinformation wird regelm\u00e4ssig aktualisiert, sobald weitere Daten und \nSicherheitsberichte verf\u00fcgbar sind.  \nComirnaty ist befristet zugelassen \u2013  siehe Rubrik \u00abEigenschaften/Wirkungen\u00bb.  \n \nComirnaty\u00ae \nZusammensetzung  \nWirkstoffe  \nTozinameranum (Einzelstr\u00e4ngige Boten- RNA [messenger RNA, mRNA] mit 5' -Cap-Struktur, durch \nzellfr eie In-vitro-Transkription mit entsprechenden DNA -Vorlagen hergestellt und f\u00fcr das Spike [S] -\nProtein des SARS -CoV-2-Virus kodierend).  \nDas  Produkt enth\u00e4lt nicht replizierende nukleosidmodifizierte mRNA.  \n \nHilfsst offe \nALC-0315 (= [(4 -Hydroxybutyl)azandiyl]bis(hexan- 6,1-diyl)bis(2 -hexyldecanoat)), ALC -0159 (=2 -\n[(Polyethylenglycol) -2000] -N,N-ditetradecylacetamid), DSPC (= 1,2- Distearoyl- sn-glycero -3 \nphosphocholin), cholesterolum, kalii chloridum (entspr. 0.005 mg Kalium pro Dosis), kalii \ndihydrogenophosphas (e ntspr. 0.003 mg Kalium pro Dosis), natrii chloridum (entspr. 0.141  mg \nNatrium pro Dosis), dinatrii phosphas dihydricus (entspr. 0.017 mg Natrium pro Dosis), saccharum, \naqua ad iniectabilia.  \nNatriumgehalt pro Dosis: 0.16  mg. \nKaliumgehalt pro Dosis: 0.01 mg. \n \nDarreichungsform  und Wirkstoffmenge pro Einheit  \nKonzentrat zur Herstellung einer Injektionsdispersion (steriles Konzentrat) zur intramuskul\u00e4ren \nAnwendung.  \nDer Impfstoff ist eine weisse bis gebrochen weisse gefrorene Dispersion (pH: 6.9\u2013 7.9). \nEs handelt  sich um eine Mehrfachdosis -Durchstechflasche.   \n \nFachinformation f\u00fcr Humanarzneimittel  \n   2 / 21 Das Konzentrat muss vor Anwendung verd\u00fcnnt werden. Eine Durchstechflasche (0.45 ml) enth\u00e4lt \nnach dem Verd\u00fcnnen bis zu 6 Dosen zu je 0.3 ml. \n1 Dosis (0.3  ml) enth\u00e4lt 30 \u00b5g COVID -19-mRNA -Impfstoff (in Lipid -Nanopartikel eingebettet).  \n \nIndikationen/ Anwendungsm\u00f6glichkeiten  \nComirnaty ist indiziert f\u00fcr die aktive Immunisierung zur Vorbeugung der durch das SARS -CoV-2-Virus \nhervorgerufenen COVID -19-Erkrankung bei Personen ab 16  Jahren.  \nDer Comirnaty -Impfstoff sollte gem\u00e4ss offiziellen Empfehlungen angewendet werden.  \n Dosierung/ Anwendung  \nR\u00fcckverfolgbarkeit  \nDem Impfempf\u00e4nger oder seiner Betreuungsperson ist eine R\u00fcckverfolgbarkeits - und \nImpferinnerungskarte auszuh\u00e4ndigen, auf welcher der Name des Impfstoffs, die Charg ennummer, die \nm\u00f6glichen Meldestellen und das Datum vermerkt sind, an dem die betreffende Person zur \nVerabreichung der zweiten Dosis Comirnaty erscheinen muss.  \nUm die R\u00fcckverfolgbarkeit biologischer Arzneimittel zu verbessern, sollten der Name und die \nCharg ennummer des verabreichten Produkts eindeutig dokumentiert werden.  \n \nPersonen ab 16 Jahren  \nComirnaty wird nach Verd\u00fcnnung in einer Impfserie mit 2 Dosen (je 0.3 ml) intramuskul\u00e4r verabreicht . \nEs wird empfohlen, die zweite Dosis 3 Wochen nach der ersten Dosi s zu verabreichen (siehe Rubrik \n\u00abWarnhinweise und Vorsichtsmassnahmen\u00bb und \u00abEigenschaften/Wirkungen\u00bb).  \nEs liegen keine Daten zu einer m\u00f6glichen Austauschbarkeit von Comirnaty mit anderen COVID -19-\nImpfstoffen zur Vervollst\u00e4ndigung der Impfserie vor. Personen, die 1  Dosis Comirnaty erhalten haben, \nsollten zur Vervollst\u00e4ndigung der Impfserie eine zweite Dosis Comirnaty erhalten.  \nF\u00fcr weitere Angaben zur Wirksamkeit, siehe Rubrik \u00abEigenschaften/Wirkungen\u00bb.  \n Kinder und Jugendliche  \nDie Sicherheit und Wirksamkeit bei Kindern und Jugendlichen unter 16 Jahren sind noch nicht belegt. \nEs stehen Daten in begrenztem Umfang zur Verf\u00fcgung.  \n  \n \nFachinformation f\u00fcr Humanarzneimittel  \n   3 / 21 \u00c4ltere Personen  \nBei \u00e4lteren Personen \u226565 Jahren ist keine Dosierungsanpassung erforderlich.  \n \nArt der Verabreichung  \nComirnaty ist  nach dem Verd\u00fcnnen intramuskul\u00e4r zu verabreichen (siehe Rubrik \u00abSonstige Hinweise \n\u2013 Hinweise f\u00fcr die Handhabung\u00bb).  \nNach dem Verd\u00fcnnen enthalten die Durchstechflaschen von Comirnaty sechs Dosen von je 0.3 ml \ndes Impfstoffs. Um 6  Dosen aus einer einzelnen D urchstechflasche zu entnehmen, sollten Spritzen \nund/oder Nadeln mit geringem Totvolumen verwendet werden. Die Kombination aus Spritze und \nNadel mit geringem Totvolumen sollte ein Totvolumen von nicht mehr als 35 Mikrolitern haben. Wenn \nStandardspritzen und -nadeln verwendet werden, reicht das Volumen m\u00f6glicherweise nicht aus, um \neine sechste Dosis aus einer einzelnen Durchstechflasche zu entnehmen.  \nUnabh\u00e4ngig vom Typ der Spritze und Nadel:  \n- Jede Dosis MUSS 0.3 ml des Impfstoffes enthalten.  \n- Wenn die in der Du rchstechflasche verbleibende Impfstoffmenge nicht f\u00fcr eine volle Dosis von \n0.3 ml ausreicht, entsorgen Sie die Durchstechflasche mit dem \u00fcbersch\u00fcssigen Volumen.  \n- \u00dcbersch\u00fcssiger Impfstoff von mehreren Durchstechflaschen darf nicht zusammengef\u00fchrt \nwerden.  \nDie bevorzugte Injektionsstelle ist der Deltamuskel (Musculus deltoideus) am Oberarm.  \nDer Impfstoff darf nicht intravaskul\u00e4r, subkutan oder intradermal injiziert werden.  \n \nDer Impfstoff darf nicht in derselben Spritze mit anderen Impfstoffen oder Arzneimitteln gemischt \nwerden.  \n Vorsichtsmassnahmen, die vor der Verabreichung des Impfstoffs zu beachten sind, sind in der Rubrik \n\u00abWarnhinweise und Vorsichtsmassnahmen\u00bb aufgef\u00fchrt.  \nF\u00fcr weitere Hinweise zum Auftauen, zur Handhabung und zur Entsorgung des Impfstoffs siehe Rubrik \n\u00abSonstige Hinweise \u2013  Hinweise f\u00fcr die Handhabung\u00bb.  \n \nKontraindikationen  \n\u00dcberempfindlichkeit gegen\u00fcber dem Wirkstoff oder einem der Hilfsstoffe.   \n \nFachinformation f\u00fcr Humanarzneimittel  \n   4 / 21  \nWarnhinweise und Vorsichtsmassnahmen  \nAllgemeine Empfehlungen \n\u00dcberempfindlichkeit und Anaphylaxie \nEs wurden F\u00e4lle von Anaphylaxie berichtet. F\u00fcr den Fall einer anaphylaktischen Reaktion nach der \nVerabreichung des Impfstoffs sollte immer eine angemessene medizinische Behandlung und \u00dcberwachung gew\u00e4hrleistet sein.  \nNach der Impfung wird eine engmaschige B eobachtung von mindestens 15 Minuten empfohlen. Eine \nzweite Dosis des Impfstoffs sollte nicht an Personen verabreicht werden, bei denen eine Anaphylaxie \nnach der ersten Dosis von Comirnaty aufgetreten ist.  \n \nAngstbedingte Reaktionen \nAngstbedingte Reaktionen, einschliesslich vasovagaler Reaktionen (Synkope), Hyperventilation oder \nstressbedingte Reaktionen k\u00f6nnen in Zusammenhang mit der Impfung als psychogene Reaktion auf die Injektion mit einer Nadel auftreten. Es ist wichtig, Vorsicht smassnahmen zur Vermeidung von \nVerletzungen infolge einer Ohnmacht zu treffen.  \n \nGleichzeitige Erkrankung  \nBei Personen, die an einer akuten schweren fieberhaften Erkrankung oder einer akuten Infektion \nleiden, sollte die Impfung verschoben werden.  \n \nThrombozy topenie und Gerinnungsst\u00f6rungen  \nWie bei anderen intramuskul\u00e4ren Injektionen sollte der Impfstoff bei Personen, die eine Therapie mit \nAntikoagulantien erhalten, oder bei Personen mit Thrombozytopenie oder einer Gerinnungsst\u00f6rung \n(z.B. H\u00e4mophilie) mit Vorsic ht verabreicht werden, da bei diesem Personenkreis nach einer \nintramuskul\u00e4ren Verabreichung Blutungen oder Bluterg\u00fcsse auftreten k\u00f6nnen.  \n \nImmungeschw\u00e4chte Personen Die Wirksamkeit, Sicherheit und Immunogenit\u00e4t des Impfstoffs wurden bei immungeschw\u00e4chten \nPersonen, einschliesslich Personen unter immunsuppressiver Behandlung, nicht untersucht. Die \nWirksamkeit von Comirnaty kann bei immunsupprimierten Personen verringert sein.  \n  \n \nFachinformation f\u00fcr Humanarzneimittel  \n   5 / 21 Dauer des Schutzes  \nDie Dauer des durch den Impfstoff induzierten Schutzes ist nicht bekannt, da sie noch in laufenden \nklinischen Studien ermittelt wird.  \n \nEinschr\u00e4nkungen der Effektivit\u00e4t des Impfstoffs  \nWie bei jedem Impfstoff sch\u00fctzt die Impfung mit Comirnaty m\u00f6glicherweise nicht jeden Geimpften. \nPersonen sind m\u00f6glicherweise erst 7 Tage nach ihrer zweiten Impfdosis vollst\u00e4ndig gesch\u00fctzt.  \n \nHilfsstoffe von besonderem Interesse  \nDieses Arzneimittel enth\u00e4lt Kalium, jedoch weniger als 1  mmol (39  mg) Kalium pro Dosis, d.h., es ist \nnahezu \u00abkaliumfrei\u00bb.  \nDieses Arzneimittel enth\u00e4lt weniger als 1 mmo l Natrium (23  mg) pro Dosis, d.h., es ist nahezu \n\u00abnatriumfrei\u00bb.  \n \nInteraktionen  \nEs wurden keine Interaktionsstudien durchgef\u00fchrt.  \nDie gleichzeitige Verabreichung von Comirnaty mit anderen Impfstoffen wurde nicht untersucht.  \n \nSchwangerschaft, Stillzeit  \nSchwangerschaft  \nEs liegen nur begrenzte Erfahrungen zur Anwendung von Comirnaty bei Schwangeren vor. \nTierexperimentelle Studien weisen nicht auf direkte oder indirekte sch\u00e4dliche Wirkungen in Bezug auf \nSchwangerschaft, embryonale/f\u00f6tale Entwicklung, Geburt  oder postnatale Entwicklung hin (siehe \nRubrik  \u00abPr\u00e4klinische Daten\u00bb). Die Verabreichung von Comirnaty in der Schwangerschaft sollte nur in \nBetracht gezogen werden, wenn der potenzielle Nutzen die m\u00f6glichen Risiken f\u00fcr Mutter und F\u00f6tus \n\u00fcberwiegt.  \n \nStillzeit  \nEs ist nicht bekannt ob Comirnaty in die Muttermilch \u00fcbergeht.  \n  \n \nFachinformation f\u00fcr Humanarzneimittel  \n   6 / 21 Fertilit\u00e4t  \nTierexperimentelle Studien ergaben  keine Hinweise auf  direkte oder  indirekte  gesundheitssch\u00e4dliche \nWirkungen in Bezug  auf eine Reproduktionstoxizit\u00e4t  (siehe Rubrik \u00abPr\u00e4klinische Daten\u00bb).  \n \nWirkung auf die Fahrt\u00fcchtigkeit und auf das Bedienen von Maschinen \nComirnaty hat keinen oder einen vernachl\u00e4ssigbaren Einfluss auf die Fahrt\u00fcchtigkeit und die \nF\u00e4higkeit zum Bedienen von Maschinen. Jedoch k\u00f6nnen einige der in der Rubrik \u00abUnerw\u00fcnsc hte \nWirkungen\u00bb aufgef\u00fchrten Wirkungen die Fahrt\u00fcchtigkeit oder die F\u00e4higkeit, Maschinen zu bedienen, \nvor\u00fcbergehend beeintr\u00e4chtigen.  \n \nUnerw\u00fcnschte Wirkungen \nZusammenfassung des Sicherheitsprofils  \nDie Sicherheit von Comirnaty wurde bei Teilnehmenden ab einem Alter von 16 Jahren in 2 klinischen \nStudien beurteilt, in die 21\u2019744 Teilnehmende eingeschlossen waren, die mindestens eine Dosis \nComirnaty erhielten . \nIn Studie  2 erhielten insgesamt 21'720  Teilnehmende ab 16  Jahren mindestens 1  Dosis Comirnaty  \nund insgesamt 21'728 Teilnehmende ab 16  Jahren Placebo (darunter 138 Jugendliche im Alter von \n16 und 17  Jahren in der Impfstoffgruppe und 145 Jugendliche im Alter von 16 und  17 Jahren in der \nPlacebo- Gruppe). Insgesamt 20'519  Teilnehmende ab 16  Jahren erhi elten 2 Dosen Comirnaty.  \nZum Zeitpunkt der Auswertung von Studie 2 wurden insgesamt 19'067 Teilnehmende (9\u2019531 in der \nComirnaty - und 9'536 in der Placebo- Gruppe) ab einem Alter von 16 Jahren \u00fcber mindestens \n2 Monate nach der zweiten Dosis Comirnaty auf die Sicherheit untersucht. Darunter waren insgesamt \n10'727 (5'350 Comirnaty und 5'377 Placebo) Teilnehmende im Alter von 16 bis 55 Jahren und \ninsgesamt 8'340 (4'181 Comirnaty und 4'159 Placebo) Teilnehmende ab 56 Jahren.  \nDie h\u00e4ufigsten unerw\u00fcnschten Wirkungen  bei Teilnehmenden ab 16 Jahren waren Schmerzen an der \nInjektionsstelle (>80%), Erm\u00fcdung (>60%), Kopfschmerzen (>50%), Myalgie und Sch\u00fcttelfrost \n(>30%), Arthralgie (>20%), Fieber und Schwellung an der Injektionsstelle (>10%), die in der Regel von leichter bis mittelstarker Intensit\u00e4t waren und sich innerhalb weniger Tage nach der Impfung \nzur\u00fcckbildeten.  Eine etwas geringere H\u00e4ufigkeit von Reaktogenit\u00e4tsereignissen war mit h\u00f6herem \nAlter assoziiert.  \n  \n \nFachinformation f\u00fcr Humanarzneimittel  \n   7 / 21 Liste der unerw\u00fcnschten Wirkungen  aus klinischen Studien und aus der Postmarketingphase \nDie unerw\u00fcnschten Wirkungen sind nach MedDRA -Systemorganklassen und H\u00e4ufigkeit gem\u00e4ss \nfolgender Konvention geordnet: \u00absehr h\u00e4ufig\u00bb (\u22651/10), \u00abh\u00e4ufig\u00bb (\u22651/100 bis <1/10), \u00abgelegentlich\u00bb \n(\u22651/1\u2019000 bis <1/ 100), \u00abselten\u00bb (\u22651/10\u2019000 bis <1/1\u2019000), \u00ab sehr selten\u00bb (<1/10\u2019000), \u00abnicht bekannt\u00bb \n(kann auf Grundlage der verf\u00fcgbaren Daten nicht gesch\u00e4tzt werden).  \n \nErkrankungen des Blutes und des Lymphsystems  \nGelegentlich: Lymphadenopathie.  \n Erkrankungen  des Immunsys tems  \nGelegentlich: \u00dcberempfindlichkeitsreaktionen (z.B. Ausschlag, Pruritus, Urtikaria\na, Angio\u00f6dema)1. \nNicht bekannt:  Anaphylaxie.  \na Urtikaria und Angio\u00f6dem wurden mit der H\u00e4ufigkeit \u00abselten\u00bb gem eldet . \n \nPsychiatrische Erkrankungen \nGelegentlich: Schlaflosigkeit.  \n Erkrankungen des Nervensystems  \nSehr h\u00e4ufig : Kopfschmerzen (55.1%).  \nSelten: akute periphere Fazialisparese\nb. \nb W\u00e4hrend des Sicherheitsnachbeobachtungszeitraums  bis 14. November 2020 wurde von vier \nTeilnehmenden in der COVID -19-mRNA -Impfstoffgruppe eine akute periphere Fazialisparese (oder \nGesichtsl\u00e4hmung) berichtet. Der Beginn war am Tag 37 nach Dosis  1 (der Teilnehmende erhielt keine \nzweite Dosis) und an den Tagen 3, 9 und 48 nach Dosis  2. In der Placebogruppe wurden keine F\u00e4lle \nvon akuter  peripherer Fazialisparese (oder Gesichtsl\u00e4hmung) berichtet.  \n \nErkrankungen des Gastrointestinaltrakts  \nSehr h\u00e4ufig : Diarrh oec (15.7%).  \n                                                \n1 Module 2.5 Clinical Overview Clinical Overview -  anaphylaxis & hypersensitivity   \n \nFachinformation f\u00fcr Humanarzneimittel  \n   8 / 21 H\u00e4ufig:  \u00dcbelkeit , Erbrechenc. \nc In der Postmarketingphase gemeldet.  \n \nSkelettmuskulatur -, Bindegewebs - und Knochenerkrankungen  \nSehr h\u00e4ufig : Arthralgie (23.6%), Myalgie (38.3%).  \nGelegentlich: Schmerzen in den Extremit\u00e4tend. \nd Bezieht sich auf den geimpften Arm.23 \n \nAllgemeine Erkrankungen und Beschwerden am Verabreichungsort  \nSehr h\u00e4ufig : Schmerzen an der Injektionsstelle (84.1%), Erm\u00fcdung (62.9%), Sch\u00fcttelfrost (31.9%), \nFiebere (14.2%), Schwellung an der Injektionsstelle (10.5%).  \nH\u00e4ufig:  R\u00f6tung an der Injektionsstelle.  \nGelegentlich:  Unwohlsein, Juckreiz an der Injektionsstelle.  \ne Nach der 2.  Dosis wurde eine h\u00f6her e H\u00e4ufigkeit von Fieber beobachtet.  \n \nDas Sicherheitsprofil bei 545 Teilnehmenden, die Comirnaty erhielten und bei Studienbeginn \nseropositiv f\u00fcr SARS -CoV-2 waren, \u00e4hnelte dem der Allgemeinpopulation.  \n \nDie Meldung des Verdachts auf Nebenwirkungen nach der Zulassung ist von grosser Wichtigkeit. Sie \nerm\u00f6glicht eine kontinuierliche \u00dcberwachung des Nutzen- Risiko -Verh\u00e4ltnisses des Arzneimittels. \nAngeh\u00f6rige von Gesundheitsberufen sind aufgefordert, jeden Verdacht einer neuen oder \nschwerwiegenden Nebenwirkung \u00fcber das Online- Portal ElViS (Electronic Vigilance System) \nanzuzeigen. Informationen dazu finden Sie unter www.swissmedic.ch . \n \n                                                \n2 Module 2.5 Clinical Overview to Support Inclusion of Pain in Extremity, Diarrhea, and Vomiting as Adverse \nDrug Reactions  \n3 Module 2.5 Clinical Overview Addendum - Global Label update- Pain in Extremity (arm)   \n \nFachinformation f\u00fcr Humanarzneimittel  \n   9 / 21 \u00dcberdosierung  \nDaten zur \u00dcberdosierung liegen von 52  Studienteilnehmenden vor, die aufgrund eines \nVerd\u00fcnnungsfehlers in der klinischen Studie 58 \u00b5g Comirnaty erhalten haben. Die Geimpften \nberichteten weder \u00fcber eine Zunahme der Reaktogenit\u00e4t noch \u00fcber unerw\u00fcnschte Reakti onen.  \nIm Falle einer \u00dcberdosierung wird eine \u00dcberwachung der Vitalfunktionen und gegebenenfalls eine \nsymptomatische Behandlung empfohlen.  \n \nEigenschaften/ Wirkungen \nATC-Code \nJ07BX  \n \nWirkungsmechanismus  \nDie nukleosidmodifizierte messenger RNA in Comirnaty ist in Lipid -Nanopartikel verpackt, welche die \nAufnahme der nicht replizierenden RNA in Wirtszellen gestatten,  und regelt so die transiente \nExpression des SARS -CoV-2-S-Antigens. Die  mRNA kodiert f\u00fcr membranverankertes Spike -(S)-\nAntigen in voller L\u00e4nge mit zwei Punktmutationen innerhalb der zentralen Helix. Die Mutation dieser \nbeiden Aminos\u00e4uren zu Prolinen fixiert das S -Antigen in einer antigenisch bevorzugten Pr\u00e4 -Fusions -\nKonformation. Der Impfstoff l\u00f6st sowohl die Produktion neutralisierender Ant ik\u00f6rper als auch eine \nzellul\u00e4re Immunantwort gegen das Spike- (S)-Antigen aus und k\u00f6nnte auf diese Weise zu einem \nSchutz vor COVID -19 beitragen.  \n \nPharmakodynamik  \nKeine weiteren Angaben.  \n \nKlinische Wirksamkeit  \nWirksamkeit  \nBei Studie 2 handelt es sich um eine multizentrische, multinationale, randomisierte, \nplacebokontrollierte, beobachterverblindete Phase- I/II/III -Studie zur Dosisfindung, zur Auswahl des \nImpfstoffkandidaten und zur Untersuchung der Wirksamkeit bei Teilnehmenden ab einem Alter von \n12 Jahren . Die Randomisierung erfolgte stratifiziert nach Alter: 12 bis 15 Jahre, 16 bis 55 Jahre bzw. \n56 Jahre und \u00e4lter. Mindestens 40% der Teilnehmenden befanden sich im Stratum \u226556  Jahre. Aus \nder Studie ausgeschlossen waren immungeschw\u00e4chte Personen und Personen mit fr\u00fcherer klinischer  \n \nFachinformation f\u00fcr Humanarzneimittel  \n   10 / 21 oder mikrobiologischer COVID -19-Diagnose. Personen mit vorbestehender stabiler Erkrankung, \ndefiniert als Erkrankung, f\u00fcr die in den 6 Wochen vor der Aufnahme in die Studie keine erhebliche \nTherapieumstellung oder Hospitalisierung aufgrund einer Krankheitsverschlechterung erforderlich \nwar, wurden ebenso eingeschlossen wie Personen mit bekannter stabiler Infektion mit Humanem \nImmundefizienz -Virus (HIV), Hepatitis -C-Virus (HCV) oder Hepatitis -B-Virus (HBV). Zum Zeitpunkt \nder Auswertun g von Studie 2 basieren die vorgestellten Angaben auf Daten von Teilnehmenden ab \n16 Jahren.  \n \nWirksamkeit bei Teilnehmenden ab 16 Jahren  \nF\u00fcr den Phase- II/III-Studienabschnitt wurden etwa 44\u2019000 Teilnehmende zu gleichen Teilen \nrandomisiert und sollten im Abs tand von 21  Tagen 2  Dosen des COVID -19-mRNA -Impfstoffs oder \nPlacebo erhalten. Die Wirksamkeitsanalysen umfassten Teilnehmende, die ihre zweite Impfung \ninnerhalb von 19 bis 42  Tagen nach ihrer ersten Impfung erhielten.  Die Mehrheit (93.1%) der \nGeimpften erhielt die zweite Dosis 19 bis 23  Tage nach Dosis  1. Eine Nachbeobachtung der \nTeilnehmenden \u00fcber einen Zeitraum von bis zu 24 Monaten nach Dosis  2 ist geplant, um die \nSicherheit und Wirksamkeit des Impfstoffs gegen COVID -19 zu beurteilen. In der klinischen S tudie \nmussten die Teilnehmenden, um entweder Placebo-  oder den COVID -19-mRNA -Impfstoff zu \nerhalten, ein Mindestintervall von 14 Tagen vor und nach der Verabreichung eines Influenza-\nImpfstoffs einhalten. In der klinische Studie  war es Teilnehmern innerhalb 60 Tagen vor Anmeldung \nund bis zum Abschluss der Studie nicht gestattet Blut -/Plasmaprodukte oder Immunglobuline zu \nerhalten.  \n \nDie Studienpopulation f\u00fcr die Auswertung des prim\u00e4ren Wirksamkeitsendpunkts umfasste \n36\u2019621 Teilnehmende ab einem Alter von 12  Jahren (18\u2019242 in der COVID -19-mRNA -Impfstoffgruppe \nund 18\u2019379 in der Placebogruppe), bei denen bis 7 Tage nach Erhalt der zweiten Dosis keine \nvorbestehende Infektion mit SARS -CoV-2 nachgewiesen wurde. Ausserdem waren \n134 Teilne hmende im Alter von 16 bis 17 Jahren (66 in der COVID -19-mRNA -Impfstoffgruppe und 68 \nin der Placebogruppe) und 1\u2019616 Teilnehmende 75 Jahre und \u00e4lter (804 in der COVID -19-mRNA -\nImpfstoffgruppe und 812 in der Placebogruppe).  \nTabelle 1:  Demografische Daten (P opulation f\u00fcr den prim\u00e4ren Wirksamkeitsendpunkt)a \n Comirnaty  \n(N=18\u2019242)  \nn (%)  Placebo  \n(N=18\u2019379)  \nn (%)  \nGeschlecht    \nM\u00e4nnlich  9\u2019318 (51.1)  9\u2019225 (50.2)  \nWeiblich  8\u2019924 (48.9)  9\u2019154 (49.8)  \nAlter (Jahre)     \n \nFachinformation f\u00fcr Humanarzneimittel  \n   11 / 21  Comirnaty  \n(N=18\u2019242)  \nn (%)  Placebo  \n(N=18\u2019379)  \nn (%)  \nMittelwert (SD)  50.6 (15.70)  50.4 (15.81)  \nMedian  52.0 52.0 \nMin.; Max.  (12; 89)  (12; 91)  \nAltersgruppe    \n\u226512 bis 15  Jahre  46 (0.3)  42 (0.2)  \n\u226516 bis 17  Jahre  66 (0.4)  68 (0.4)  \n\u226516 bis 64  Jahre  14\u2019216 (77.9)  14\u2019299 (77.8)  \n\u226565 bis 74  Jahre  3\u2019176 (17.4)  3\u2019226 (17.6)  \n\u226575 Jahre  804 (4.4)  812 (4.4)  \n75 bis 85  Jahre  799 (4.4)  807 (4.4)  \n>85 Jahre  5 (0.0)  5 (0.0)  \nHautfarbe    \nWeiss  15\u2019110 (82.8)  15\u2019301 (83.3)  \nSchwarz oder Afro -Amerikanisch  1\u2019617 (8.9)  1\u2019617 (8.8)  \nIndigene Amerikaner oder Alaskaner  118 (0.6)  106 (0.6)  \nAsiatisch  815 (4.5)  810 (4.4)  \nIndigene Hawaiianer oder andere \npazifische Inselbewohner  48 (0.3)  29 (0.2)  \nSonstigeb 534 (2.9)  516 (2.8)  \nEthnizit\u00e4t    \nHispanisch oder Latino  4\u2019886 (26.8)  4\u2019857 (26.4)  \nNicht hispanisch oder Latino  13\u2019253 (72.7)  13\u2019412 (73.0)  \nKeine Angabe  103 (0.6)  110 (0.6) \nKomorbidit\u00e4tenc   \nJa 8\u2019432 (46.2)  8\u2019450 (46.0)  \nNein 9\u2019810 (53.8)  9\u2019929 (54.0)  \na. Alle geeigneten randomisierten Teilnehmenden, die alle Impfungen wie randomisiert innerhalb des \nvordefinierten Zeitfensters erhalten, nach Ermessen des Klinikers ansonsten keine wichtigen \nProtokollabweichungen aufweisen und bei denen bis Ablauf von 7 Tagen nach Dosis  2 kein Nachweis \neiner SARS -CoV-2-Infektion vorliegt.  \nb. Einschliesslich gemischte Abstammung und keine Angabe.  \nc. Anzahl der Teilnehmenden mit 1 oder mehr der folgenden Komorbidit\u00e4ten, die das Risiko eines schweren \nCOVID -19-Verlaufs erh\u00f6hen \n\u2022 Chronische Lungenerkrankung (z.B. Emphysem und chronische Bronchitis, idiopathische \nLungenfibrose und zystische Fibrose) oder mittelschweres bis schweres Asthma \n\u2022 Signifikante Herzerkrankung (z.B. Herzinsuffizienz, koronare Herzkrankheit, angeborener Herzfehler, \nKardiomyopathien und pulmonale Hypertonie)  \n\u2022 Adipositas (K\u00f6rpermasseindex [Body Mass Index] \u226530  kg/m2) \n\u2022 Diabetes (Typ 1, Typ  2 oder Gestationsdiabetes)  \n\u2022 Lebererkrankung \n\u2022 Infektion mit dem Humanen Immundefizienz -Virus (HIV) (nicht in der Wirksamkeitsauswertung \nber\u00fccksichtigt)  \n \nWirksamkeit gegen COVID -19 \nZum Zeitpunkt der prim\u00e4ren Wirksamkeitsanalyse wurden die Teilnehmenden f\u00fcr insgesamt 2\u2019214 \nPersonenjahre in der COVID -19-mRNA -Impfstoffgruppe und f\u00fcr insgesamt 2\u2019222 Personenjahre in \nder Placebogruppe auf symptomatisches COVID -19 untersucht.   \n \nFachinformation f\u00fcr Humanarzneimittel  \n   12 / 21 Es wurden kei ne bedeutsamen klinischen Unterschiede in Bezug auf die Gesamtwirksamkeit des \nImpfstoffs bei Teilnehmenden mit Risiko eines schweren Verlaufs von COVID -19 festgestellt, \neinschliesslich Teilnehmenden mit mindestens 1 Begleiterkrankung, die das Risiko f\u00fcr ei nen \nschweren Verlauf von COVID -19 erh\u00f6ht (z.B. Asthma, K\u00f6rpermasseindex [Body Mass Index, BMI] \n\u226530 kg/m2, chronische Lungenerkrankung, Diabetes mellitus, Hypertonie).  \nDie Informationen zur Wirksamkeit des Impfstoffs sind in Tabelle 2 aufgef\u00fchrt.  \nTabelle 2: Wirksamkeit des Impfstoffs \u2013  Erstes Auftreten von COVID -19 ab 7 Tage nach Dosis  2, \nnach Altersuntergruppen \u2013  Teilnehmende ohne Nachweis einer Infektion vor Ablauf von 7  Tagen \nnach Dosis  2 \u2013 auswertbare Wirksamkeitspopulation (7 Tage)  \nErstes Auftreten von COVID -19 ab 7  Tage nach Dosis  2 bei Teilnehmenden ohne \nNachweis einer fr\u00fcheren SARS -CoV-2-Infektion*  \nUntergruppe  COVID -19-mRNA -\nImpfstoff \nNa = 18\u2019198 \nF\u00e4lle  \nn1b \nBeobachtungszeitc \n(n2d) Placebo  \n \nNa = 18\u2019325 \nF\u00e4lle  \nn1b \nBeobachtungszeitc \n(n2d) Wirksamkeit des \nImpfstoffs  \n% (95% -KI)f \n  Alle Probandene 8 \n2.214 (17\u2019411)  162 \n2.222 (17\u2019511)  95.0 (90 .0; 97 .9)  \n  16 bis 64  Jahre  7 \n1.706 (13\u2019549)  143 \n1.710 (13\u2019618)  95.1 (89 .6; 98 .1) \n  65 Jahre und \u00e4lter  1 \n0.508 (3\u2019848)  19 \n0.511 (3\u2019880)  94.7 (66 .7; 99 .9) \n  65 bis 74  Jahre  1 \n0.406 (3\u2019074)  14 \n0.406 (3\u2019095)  92.9 (53 .1; 99 .8) \n  75 Jahre und \u00e4lter  0 \n0.102 (774)   5 \n0.106 (785)   100.0 (-13.1, \n100.0)  \nHinweis: Best\u00e4tigte F\u00e4lle wurden bestimmt durch Reverse -Transkriptase -Polymerase -\nKettenreaktion (RT -PCR) und mindestens 1 auf COVID -19 hindeutendes Symptom (*Falldefinition: \n[mindestens 1 Symptom der Folgenden:] Fieber, neu aufgetretener oder verst\u00e4rkter Husten, neu \naufgetretene oder verst\u00e4rkte Atemnot, Sch\u00fcttelfrost, neu aufgetretene oder verst\u00e4rkte \nMuskelsc hmerzen, neu aufgetretener Verlust des Geschmacks - oder Geruchssinns, \nHalsschmerzen, Durchfall oder Erbrechen.)  \n*  In die Analyse gingen Teilnehmende  ein, bei denen (vor Ablauf von 7 Tagen nach Erhalt der \nletzten Dosis) kein serologischer oder virologischer Nachweis einer fr\u00fcheren SARS -CoV-2-\nInfektion vorlag (d.h. N -bindender Antik\u00f6rper [Serum] negativ bei Termin 1 und SARS -CoV-2 \nnicht durch NAAT [Nucleic Acid Amplification Technology; Nasenabstrich] nachweisbar bei Termin 1 und 2), und bei denen im Rahmen eines allf\u00e4lligen ausserplanm\u00e4ssigen Besuchs  vor \nAblauf von 7 Tagen nach Dosis  2 ein NAAT (Nasenabstrich) negativ ausfiel . \na. N = Anzahl der Teilnehmenden in der angegebenen Gruppe.  \nb. n1 = Anzahl der Teilnehmenden, welche die Endpunktdefinition erf\u00fcllen.  \nc. Gesamtbeobachtungszeit in 1\u2019000 Personenjahren f\u00fcr den jeweiligen Endpunkt \u00fcber alle \nTeilnehmenden innerhalb jeder Endpunkt -Risikogruppe. Der Zeitraum f\u00fcr die Erfassung von \nCOVID -19-F\u00e4llen erstreckt sich von 7 Tagen nach Dosis 2 bis zum Ende  des \nBeobachtungszeitraums.  \nd. n2 = Anzahl der bez\u00fcglich des Endpunkts gef\u00e4hrdeten Personen.  \ne. Es wurden keine best\u00e4tigten F\u00e4lle bei Teilnehmenden im Alter von 12 bis 15 Jahren identifiziert.  \nf. Das Konfidenzintervall (KI) f\u00fcr die Wirksamkeit des Impfstof fs wurde auf der Grundlage der \nbeobachtungszeitadjustierten Clopper -Pearson- Methode abgeleitet.  KI nicht f\u00fcr Multiplizit\u00e4t \nadjustiert.  \n  \n \nFachinformation f\u00fcr Humanarzneimittel  \n   13 / 21 In der zweiten Prim\u00e4ranalyse betrug die Wirksamkeit des COVID -19-mRNA -Impfstoffs gegen\u00fcber \nPlacebo in Bezug auf das ers te Auftreten von COVID -19 nach Ablauf von 7 Tagen nach Dosis  2 bei \nTeilnehmenden mit oder ohne Nachweis einer Infektion ab 16  Jahren 94.6% (95% -\nGlaubw\u00fcrdigkeitsintervall von 89.9 % bis 97.3  %). \nDar\u00fcber hinaus zeigten Untergruppenanalysen des prim\u00e4ren Wirks amkeitsendpunkts \u00e4hnliche \nWirksamkeitspunktsch\u00e4tzungen f\u00fcr alle Geschlechter, Hautfarben und ethnischen Gruppen sowie f\u00fcr \nTeilnehmende mit medizinischen Komorbidit\u00e4ten, die mit einem hohen Risiko f\u00fcr einen schweren COVID -19-Verlauf assoziiert sind.  \n \nWirksamkeit gegen COVID -19 mit schwerem Verlauf  \nSekund\u00e4re Wirksamkeitsanalysen deuteten auf einen Nutzen des COVID -19-mRNA -Impfstoffs \nhinsichtlich der Pr\u00e4vention von COVID -19 mit schwerem Verlauf hin, jedoch war die Anzahl der F\u00e4lle \nsehr gering.  \nDie Wirksa mkeit gegen COVID -19 mit schwerem Verlauf (wie im Studienprotokoll definiert), das \nfr\u00fchestens 7  Tage nach Dosis  2 auftrat, betrug 66.4% (95% -Glaubw\u00fcrdigkeitsintervall -124.8; 96.3) \n(1 Fall in der COVID -19-mRNA -Impfstoffgruppe und 3 F\u00e4lle in der Placebogruppe).  \n Befristete Zulassung  \nAufgrund einer zum Zeitpunkt der Begutachtung des Zulassungsgesuches unvollst\u00e4ndigen klinischen \nDatenlage, wird das Arzneimittel Comirnaty  befristet zugelassen (Art. 9a Heilmittelgesetz). Die \nbefristete Zulassung ist zwingend an die zeitgerechte Erf\u00fcllung von Auflagen gebunden. Nach deren \nErf\u00fcllung kann die befristete Zulassung in eine ordentliche Zulassung \u00fcberf\u00fchrt werden.  \n \nPharmakokinetik  \nAbsorption  \nNicht zutreffend.  \n \nDistribution  \nNicht zutreffend.  \n \nMetabolismus  \nNicht zutreffend.   \n \nFachinformation f\u00fcr Humanarzneimittel  \n   14 / 21  \nElimination  \nNicht zutreffend.  \n \nPr\u00e4klinische Daten  \nBasierend auf konventionellen Studien zur Toxizit\u00e4t bei wiederholter Gabe sowie zur Reproduktions - \nund Entwicklungstoxizit\u00e4t lassen die pr\u00e4klinischen Daten keine besonderen Gefahren f\u00fcr den \nMenschen erkennen.  \n \nAllgemeine Toxizit\u00e4t  \nRatten, denen intramuskul\u00e4r Comirnaty verabreicht wurde (einmal w\u00f6chentlich 3 volle Humandosen, \ndie bei Ratten aufgrund von K\u00f6rpergewichtsunterschieden relativ h\u00f6here Werte erzeugen), zeigten an \nder Injektionsstelle leichte \u00d6deme und Erytheme, Vergr\u00f6sserungen der lokalen Lymphknoten und der \nMilz und einen Anstieg der Leukozyten (einschliesslich Basophile und Eosinophile), was auf eine Entz\u00fcndungsreaktion hindeutet, sowie eine Vakuolisierung der portalen Hepatozyten ohne Nachweis \neiner Lebersch\u00e4digung. Alle Erscheinungen waren reversibel.  \n \nGenotoxizit\u00e4t/Karzinogenit\u00e4t  \nEs wurden weder Genotoxizit\u00e4ts - noch Karzinogenit\u00e4tsstudien durchgef\u00fchrt. Es ist nicht damit zu \nrechnen, dass die Bestandteile des Impfstoffs (Lipide und mRNA) ein genotoxisches Potential \nbesitzen.  \n \nReproduktions - und Entwicklungstoxizit\u00e4t  \nDie Reproduktions - und Entwicklungstoxizit\u00e4t wurde an Ratten in einer kombi nierten Fertilit\u00e4ts - und \nEntwicklungstoxizit\u00e4tsstudie untersucht, bei der weiblichen Ratten Comirnaty vor der Paarung und \nw\u00e4hrend der Tr\u00e4chtigkeit intramuskul\u00e4r verabreicht wurde (Gabe von 4 vollen Humandosen, die bei \nRatten aufgrund von K\u00f6rpergewichtsunterschieden relativ h\u00f6here Dosen erzeugen, und sich \nzwischen dem Tag 21 vor der Paarung und dem Tag 20 der Gravidit\u00e4t erstreckten). SARS- CoV-2 \nneutralisierende Antik\u00f6rperreaktionen waren bei den m\u00fctterlichen Tieren von vor der Paarung bis zum Ende der Studie am postnatalen Tag  21 sowie bei den F\u00f6ten und Nachkommen vorhanden. Es \nwurden keine impfstoffbedingten Wirkungen auf die weibliche Fertilit\u00e4t, die Tr\u00e4chtigkeit oder die embryof\u00f6tale Entwicklung oder auf die Entwicklung der Nachkommen festgestellt. Es liegen keine Daten zu Comirnaty zum Plazentatransfer des Impfstoffs oder zur Ausscheidung in der Milch vor.   \n \nFachinformation f\u00fcr Humanarzneimittel  \n   15 / 21  \nSonstige Hinweise  \nInkom patibilit\u00e4ten  \nDas Arzneimittel darf, au sser mit den unten unter \u00abHinweise f\u00fcr die Handhabung\u00bb aufgef\u00fchrten, nicht \nmit anderen Arzneimitteln gemischt werden.  \n \nHaltbarkeit  \nDas Arzneimittel darf nur bis zu dem auf der Packung mit \u00abEXP\u00bb bezeichneten Datum verwendet \nwerden.  \nHaltbarkeit der unge\u00f6ffneten Durchstechflasche: 6 Monate bei - 90 \u00b0C bis - 60 \u00b0C. \nAlternativ k\u00f6nnen unge\u00f6ffnete Durchstechflaschen bei -25 \u00b0C bis - 15 \u00b0C f\u00fcr insgesamt 2  Wochen \ngelag ert und transportiert werden und k\u00f6nnen einmal auf die empfohlene Lagerung stemperatur \nvon -90 \u00b0C bis - 60 \u00b0C zur\u00fcckgebracht  werden.  Die gesamte Lagerungszeit  bei -25 \u00b0C bis -15 \u00b0C sollte \n2 Wochen nicht \u00fcberschreiten.  \nNach dem Herausnehmen aus dem Gefrierschrank kann die unge\u00f6ffnete Durchstechflasche vor der \nVerwendung bis zu 5 Tage bei 2  \u00b0C bis 8  \u00b0C gelagert werden. Innerhalb der 5  Tage Haltbarkeitsdauer \nbei 2 \u00b0C bis 8  \u00b0C k\u00f6nnen bis zu 12 Stunden f\u00fcr den Transport genutzt  werden.  Vor der Verwendung \nkann die unge\u00f6ffnete Durchstechflasche bis zu 2 Stunden bei Temperaturen bis 30 \u00b0C gelagert \nwerden.  \nNach dem Auftauen darf der Impfstoff nicht erneut eingefroren werden.  \n \nHandhabung von Temperatur abweichungen  nach Entnahme aus dem Gefrierschrank  \nDie Stabilit\u00e4tsdaten zeigen, dass die unge\u00f6ffnete Durchstechflasche haltbar ist bis zu:  \n- 24 Stunden bei Aufbewahrung bei Temperaturen von - 3 \u00b0C bis 2  \u00b0C. \n- insgesamt 4 Stunden bei Aufbewahrung bei Temperaturen von 8 \u00b0C bis 30  \u00b0C; dies schliesst \ndie oben beschriebenen 2 Stunden bei bis zu 30 \u00b0C ein . \nDiese Angaben dienen nur als Orientierungshilfe f\u00fcr das medizinische Fachpersonal im Falle einer \nversehentlichen Temperaturabweichung.  \n  \n \nFachinformation f\u00fcr Humanarzneimittel  \n   16 / 21 Transfer von gefrorenen Durchstechflaschen, die bei  Ultratiefk\u00fchlung (<-60 \u00b0C) gelagert wurden  \n- Flaschentr\u00e4ger  mit geschlossenem Deckel und 195 Durchstechflaschen, die gefroren aus der \nUltrat iefk\u00fchlung (< -60 \u00b0C) entnommen w urden, k\u00f6nnen bis zu 5 Minuten bei T emperatur en bis \nzu 25 \u00b0C bleiben.  \n- Flaschentr\u00e4ger  mit ge\u00f6ffnetem Deckel, oder Flaschentr\u00e4ger  mit weniger als \n195 Durchstechflaschen, die gefroren aus der Ultratiefk\u00fchlung  (<-60 \u00b0C) entnommen wurden, \nk\u00f6nnen bis zu 3 Minuten bei Temperatur en bis zu 25 \u00b0C bleiben.  \n- Nachdem die Flaschentr\u00e4ger  nach der Exposition bei Temperatur en bis zu 25 \u00b0C wieder in die \nTiefk\u00fchlung gebracht wurden, m\u00fcssen sie mindestens 2  Stunden in der Tiefk\u00fchlung \nverbleiben, bevor sie wieder entnommen werden k\u00f6nnen.  \n \nTransfer  von gefrorenen Durchstechflaschen, die bei -25 \u00b0C bis -15 \u00b0C gelagert  wurden  \n- Flaschentr\u00e4ger  mit geschlossenem Deckel  und 195 Durchstechflaschen, die aus gefrorener \nLagerung ( -25 \u00b0C bis - 15 \u00b0C) entnommen wurden, k\u00f6nnen bis zu 3  Minuten bei Temperaturen \nbis zu 25 \u00b0C bleiben.  \n- Flaschentr\u00e4ger  mit ge\u00f6ffnetem Deckel , oder Flaschentr\u00e4ger  mit weniger als \n195 Durchstechflaschen, die aus gefrorener Lagerung ( -25 \u00b0C bis - 15 \u00b0C) entnommen wurden, \nk\u00f6nnen bis zu 1  Minute bei Temperaturen bis zu 25 \u00b0C bleiben.  \n Sobald eine Durchstechflasche aus dem Flaschentr\u00e4ger  entnommen wurde, sollte sie zur \nVerwendung aufgetaut werden.  \n \nHaltbarkeit nach Anbruch \nVerd\u00fcnntes Arzneimittel: Die chemische und physikalische Gebrauchsstabilit\u00e4t , einschliesslich des \nTransports, ist f\u00fcr einen Zeitraum von 6 Stunden bei 2 \u00b0C bis 30  \u00b0C nach Verd\u00fcnnung in \nNatriumchlo rid-Injektionsl\u00f6sung 9  mg/ml (0.9%) belegt. Aus mikrobiologischen Gr\u00fcnden sollte das \nProdukt sofort verwendet werden. Erfolgt die Anwendung nicht sofort, liegen die \nAufbewahrungszeiten und - bedingungen f\u00fcr die Verwendung in der Verantwortung des Anwenders.  \n \nBesondere Lagerungshinweise  \nTiefgek\u00fchlt bei -90 \u00b0C bis - 60 \u00b0C lagern.  \nIn der Originalverpackung aufbewahren, um den Inhalt vor Licht zu sch\u00fctzen.   \n \nFachinformation f\u00fcr Humanarzneimittel  \n   17 / 21 W\u00e4hrend der Lagerung ist die Exposition gegen\u00fcber Raumlicht so gering wie m\u00f6glich zu halten, die \nExposition gegen\u00fcber direktem Sonnenlicht und ultraviolettem Licht ist zu vermeiden.  \nAufgetaute Durchstechflaschen k\u00f6nnen bei Raumlicht gehandhabt werden.  \n \nZu den Aufbewahrungsbedingungen nach Auftauen und Verd\u00fcnnung des Arzneimittels, siehe oben \nunter \u00abHaltbarkeit\u00bb und \u00abHaltbarkeit nach Anbruch\u00bb . \nAusser Reichweite von Kindern aufbewahren.  \n \nHinweise f\u00fcr die Handhabung Comirnaty ist von einer medizinischen Fachperson unter Verwendung aseptischer Techniken \nzuzub ereiten, um die Sterilit\u00e4t der zubereiteten Dispersion sicherzustellen.  \nAUFTAUEN VOR DEM VERD\u00dcNNEN  \n \n - Die Mehrfachdosis -Durchstechflasche  \nwird gefroren gelagert und muss vor \nder Verd\u00fcnnung aufgetaut werden. \nDie gefrorenen Durchstechflaschen \nsollten zum Auftauen in eine \nUmgebung von 2 \u00b0C bis 8  \u00b0C gebracht \nwerden. Das Auftauen eines \nFlaschentr\u00e4gers mit  195 \nDurchstechflaschen kann 3 Stunden \ndauern. Alternativ k\u00f6nnen gefrorene \nDurchstechflaschen zur sofortigen \nVerwendung auch 30 Minuten lang \nbei Temperaturen bis zu 30 \u00b0C \naufgetaut werden.  \n- Die unge\u00f6ffnete Durchstechflasche  \nkann bis zu 5 Tage bei 2 \u00b0C bis 8  \u00b0C \ngelagert werden. Innerhalb der \n5 Tage  Haltbarkeitsdauer bei 2  \u00b0C bis \n8 \u00b0C k\u00f6nnen bis zu 12  Stunden f\u00fcr \nden Transport genutzt werden.  \n- Lassen Sie die aufgetaute \nDurchstechflasche auf \nRaumtemperatur kommen und drehen \nSie diese vor der Verd\u00fcnnung 10- mal \nvorsichtig um. Nicht sch\u00fctteln.  \n- Vor dem Ver d\u00fcnnen kann die \naufgetaute Dispersion weiss e bis \ngebrochen weisse undurchsichtige \namorphe Partikel enthalten.  \nNicht mehr als \n2 Stunden bei \nRaum -\ntemperatur (bis \nzu 30  \u00b0C).  \n \nFachinformation f\u00fcr Humanarzneimittel  \n   18 / 21 VERD\u00dcNNUNG  \n \n - Der aufgetaute Impfstoff muss in \nseiner urspr\u00fcnglichen \nDurchstechflasche mit 1.8 ml \nNatriumchlorid -Injektionsl\u00f6sung \n9 mg/ml (0.9%) unter Verwendung \neiner 21- Gauge - oder d\u00fcnneren Nadel \nunter aseptischen Techniken verd\u00fcnnt \nwerden.  \n \n - Gleichen Sie den Druck in der \nDurchstechflasche aus, bevor Sie die Nadel aus der Durchstechflasche \nentfernen, indem Sie 1.8  ml Luft in die \nleere Verd\u00fcnnungsmittels pritze  \nziehen.  \n \n1.8 ml von 0.9% Natriumchlorid -\nInjektionsl\u00f6sung \nZiehen Sie den Kolben bis zur 1.8  ml \nMarkierung zur\u00fcck, um Luft von der \nDurchstechflasche zu entfernen.  \n  \n \nFachinformation f\u00fcr Humanarzneimittel  \n   19 / 21  \n - Drehen Sie die verd\u00fcnnte Dispersion \n10-mal vorsichtig um. Nicht sch\u00fctteln.  \n- Der verd\u00fcnnte Impfstoff sollte als \ngebrochen weisse Dispersion ohne \nsichtbare Partikel vorliegen. \nVerwenden Sie den verd\u00fcnnten \nImpfstoff nicht , wenn Partikel oder \nVerf\u00e4rbungen vorhanden sind.  \n \n - Die Durchstechflaschen mit der \nverd\u00fcnnten Dispersion sind mit dem \nentsprechenden Datum und Uhrzeit \nder Verd\u00fcnnung zu kennzeichnen.  \n- Nach Verd\u00fcnnung bei 2 \u00baC bis 30  \u00baC \nlagern und innerhalb von 6 Stunden, \neinschliesslich jeglicher Transportzeit, \nverwenden.  \n- Die verd\u00fcnnte Dispersion nicht \neinfrieren oder sch\u00fctteln. Lassen Sie \neine gek\u00fchlte, verd\u00fcnnte Dispersion \nvor der Verwendung auf Raumtemperatur kommen.  \n \nVorsichtig  \u00d7 10 \nNotieren Sie das entsprechende \nDatum und die Uhrzeit.  \nInnerhalb von 6  Stunden nach \nVerd\u00fcnnung verwenden  \n \nFachinformation f\u00fcr Humanarzneimittel  \n   20 / 21 ZUBEREITUNG VON INDIVIDUELLEN 0.3  ml DOSEN VON COMIRNATY  \n \n - Nach der Verd\u00fcnnung enth\u00e4lt die \nDurchstechflasche 2 .25 ml, aus der \n6 Dosen zu 0. 3 ml entnommen \nwerden k\u00f6nnen.  \n- Reinigen Sie den Stopfen der \nDurchstechflasche unter aseptischen \nBedingungen mit einem \nantiseptischen Einmaltupfer.  \n- Entnehmen Sie 0. 3 ml Comirnaty.  \n Es sollten Spritzen und/oder Nadeln \nmit geringem Totvolumen verwendet \nwerden, um 6 Dosen aus einer \nDurchstechflasche zu entnehmen. Die Kombination aus Spritze und Nadel \nmit geringem Totvolumen sollte ein \nTotvolumen von nicht mehr als \n35 Mikrolitern haben.  \n \nWenn Standardspritzen und -nadeln \nverwendet werden, reicht das Volumen m\u00f6glicherweise nicht aus, \num eine sechste Dosis aus einer \neinzelnen Durchstechflasche zu \nentnehmen.  \n \n- Jede Dosis muss 0. 3 ml des \nImpfstoffs enthalten.  \n- Wenn die in der Durchstechflasche verbleibende Impfstoffmenge nicht f\u00fcr \neine volle Dosis von 0. 3 ml ausreicht, \nentsorgen Sie die Durchstechf lasche \nmit dem \u00fcbersch\u00fcssigen Volumen.  \n \n- Entsorgen Sie nicht verwendeten \nImpfstoff innerhalb von 6  Stunden \nnach der Verd\u00fcnnung.  \n \nEntsorgung  \nNicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen Anforderungen zu \nbeseitigen.  \n \nZulassungsnummer  \n68225 (Swissmedic).  \n \n0.3 ml verd\u00fcnnter \nImpfstoff  \n  \n \nFachinformation f\u00fcr Humanarzneimittel  \n   21 / 21 Packungen \n1 Packung mit 195 2 ml Mehrfachdosis -Durchstechflaschen  (Typ I -Glas) mit einem Stopfen \n(synthetischer Brombutylkautschuk)  und einer Flip- off-Kunststoffkappe mit einem Verschluss aus \nAluminium  (mit je 6 Dosen) [B].  \n \nZulassungsinhaberin  \nPfizer AG, Z\u00fcrich.  \n \nStand der Information  \nApril 2021 \n \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}